CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10128416,101284165,5,F,20130514,20150715,20140428,20150727,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19010255,BRISTOL MYERS SQUIBB,,31,YR,,M,Y,,,20150727,N,OT,ZA,ZA,EFAVIRENZ,Hyponatraemia;Tuberculosis,101284165,OT,,,101284165,1,20130422,20130507,,,101284165,1,Tuberculosis
10222671,102226712,2,F,,20130724,20140606,20150727,PER,,US-GILEAD-2013-0080205,GILEAD,,,,,M,Y,,,20150727,N,CN,US,US,SUSTIVA,Gynaecomastia,,,,,102226712,1,,2006,,,102226712,1,HIV infection
10222673,102226733,3,F,,20130925,20140606,20150727,PER,,US-GILEAD-2013-0081759,GILEAD,,,,A,M,Y,79,KG,20150727,N,MD,US,US,SUSTIVA,Drug ineffective,102226733,OT,,,102226733,1,20111103,,,,102226733,1,HIV infection
10312565,103125653,3,F,200906,20150727,20140718,20150803,EXP,,JP-009507513-1008USA00405,MERCK,,64,YR,,M,Y,,,20150803,N,CN,US,JP,EFAVIRENZ,Diabetes mellitus;Mycobacterium avium complex infection;Pancytopenia;Tuberculosis,103125653,LT,,,103125653,1,20090217,20090624,,,103125653,1,HIV infection
10393648,103936482,2,F,20140730,20140813,20140819,20150722,PER,,US-GILEAD-2014-0112056,GILEAD,,56,YR,A,M,Y,,,20150722,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pruritus;Rash,,,,,103936482,1,20140730,,,,103936482,1,HIV infection
10416236,104162362,2,F,,20130724,20140828,20150722,PER,,US-GILEAD-2013-0080143,GILEAD,,,,,M,Y,,,20150722,N,CN,US,US,SUSTIVA,Depression;Emotional distress;Gynaecomastia,,,,,104162362,1,2006,2006,,,104162362,1,HIV infection
10416273,104162732,2,F,,20131031,20140828,20150722,PER,,US-GILEAD-2013-0086862,GILEAD,,40,YR,A,M,Y,,,20150722,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain upper;Decreased appetite;Dizziness,,,,,,,,,,,104162732,1,HIV infection
10467464,104674643,3,F,20140825,20150610,20140922,20150813,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-21415971,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20150813,N,CN,US,BW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,104674643,OT,,,104674643,1,20110609,20140806,,,104674643,1,Antiretroviral therapy
10490934,104909345,5,F,,20150430,20141002,20150723,PER,,US-GILEAD-2014-0116844,GILEAD,,53,YR,A,F,Y,,,20150723,N,OT,US,US,EFAVIRENZ,Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,104909345,OT,,,104909345,1,20131028,20140410,,,104909345,1,HIV infection
10502435,105024353,3,F,20040216,20150827,20141007,20150909,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-21452552,BRISTOL MYERS SQUIBB,,45,YR,,M,Y,79,KG,20150909,N,CN,FR,FR,SUSTIVA,Vertigo,105024353,DS,,,105024353,1,20040216,20140912,,,105024353,1,HIV infection
10520186,105201862,2,F,,20141010,20141015,20150818,PER,,US-GILEAD-2014-0118545,GILEAD,,52,YR,A,F,Y,,,20150818,N,CN,US,US,SUSTIVA,Nasal congestion,,,,,105201862,1,20140814,,,,105201862,1,Product used for unknown indication
10567030,105670302,2,F,20141005,20150820,20141105,20150825,EXP,,FR-GILEAD-2014-0121194,GILEAD,,51,YR,A,M,Y,112.5,KG,20150825,N,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Myocardial infarction,105670302,OT,,,105670302,1,20100726,,,,105670302,1,HIV infection
10679686,106796863,3,F,20141127,20150716,20141229,20150720,EXP,,UG-009507513-1412UGA012531,MERCK,,23,YR,,F,Y,,,20150720,N,CN,US,UG,EFAVIRENZ,HIV associated nephropathy;Sputum abnormal,106796863,DE,,,106796863,1,20141127,20141202,,,106796863,1,HIV infection
10722714,107227145,5,F,20140823,20150720,20150120,20150727,EXP,,RU-GLAXOSMITHKLINE-B1006356A,GLAXOSMITHKLINE,,,,,M,Y,,,20150727,N,CN,RU,RU,EFAVIRENZ,Asthenia;Chest pain;Chronic gastritis;Duodenitis;Erosive oesophagitis;Gastric disorder;Gastric polyps;Gastritis haemorrhagic;Gastrooesophageal reflux disease;Head discomfort;Headache;Hiatus hernia;Hyperchlorhydria;Influenza like illness;Initial insomnia;Irritability;Lymph node pain;Musculoskeletal discomfort;Nail discolouration;Nasal obstruction;Nasopharyngitis;Nervousness;Neurosis;Oropharyngeal pain;Pharyngeal disorder;Pharyngeal erosion;Pharyngeal erythema;Pharyngitis;Pyrexia;Respiratory tract infection viral;Rhinorrhoea;Tongue coated;Tonsillar inflammation,107227145,OT,,,107227145,1,201312,,,,107227145,1,HIV infection
10725596,107255964,4,F,20141001,20150804,20150121,20150812,EXP,,CA-009507513-1501CAN005781,MERCK,,34,YR,,F,Y,,,20150812,N,CN,CA,CA,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy,107255964,OT,,,107255964,1,20140916,20140916,,,107255964,1,Hepatitis C
10783699,107836992,2,F,20141231,20150811,20150210,20150825,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-006543,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,54.2,KG,20150825,N,CN,US,ZW,EFAVIRENZ,Anaemia;Dysfunctional uterine bleeding;Polycystic ovaries,107836992,LT,,,107836992,1,20080630,,,,107836992,1,HIV infection
10783942,107839422,2,F,,20150824,20150210,20150826,EXP,,IN-AUROBINDO-AUR-APL-2015-01044,AUROBINDO,LINGESWARAN A.. ANTIRETROVIRALS CATATONIA: CASE REPORT. REACTIONS WEEKLY. 2015;1565:36,16,YR,,M,Y,,,20150826,N,OT,IN,IN,Efavirenz Tablets,Agitation;Catatonia;Drug withdrawal syndrome;Echopraxia;Grimacing;Mutism;Negativism;Poor quality sleep;Posturing,107839422,OT,,,,,,,,,107839422,1,Antiretroviral therapy
10860716,108607162,2,F,,20150805,20150224,20150808,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-003682,BRISTOL MYERS SQUIBB,,,,,M,Y,3.1,KG,20150808,N,OT,AR,AR,EFAVIRENZ,Foetal exposure during pregnancy;Plagiocephaly,108607162,OT,,,,,,,,,108607162,1,Product used for unknown indication
10862465,108624654,4,F,20141011,20150521,20150224,20150729,EXP,,GB-GILEAD-2015-0137682,GILEAD,,51,YR,A,F,Y,66,KG,20150729,N,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nephrolithiasis,108624654,OT,,,108624654,1,20100617,,,,108624654,1,HIV infection
10865804,108658043,3,F,20140701,20150708,20150224,20150716,EXP,,UG-GILEAD-2014-0120166,GILEAD,,29,YR,A,F,Y,56,KG,20150716,N,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Abortion threatened;Amylase increased;Exposure during pregnancy;Upper respiratory tract infection;Vulvovaginal candidiasis,108658043,OT,,,108658043,1,20140701,20140923,,,108658043,1,HIV infection
10955026,109550262,2,F,20110531,20150909,20150325,20150921,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-016752,BRISTOL MYERS SQUIBB,,41,YR,,F,Y,,,20150921,N,MD,GB,GB,SUSTIVA,Colectomy;Colon cancer,109550262,OT,,,109550262,1,20060214,,,,109550262,1,HIV infection
10962723,109627234,4,F,20141013,20150821,20150327,20150827,EXP,,TR-GILEAD-2015-0137308,GILEAD,,61,YR,A,M,Y,80,KG,20150827,N,MD,TR,TR,EFAVIRENZ,Chronic kidney disease;Nephropathy toxic;Overdose,109627234,OT,,,109627234,1,20140917,20141014,,,109627234,1,HIV infection
10983530,109835302,2,F,,20150629,20150403,20150707,EXP,,US-BMSGILMSD-2015-0145189,GILEAD,,37,YR,A,F,Y,,,20150707,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,CD4 lymphocytes decreased;Diabetes mellitus;Drug ineffective;Drug interaction;Drug resistance;Gastrooesophageal reflux disease;HIV test positive;Hypertension;Pregnancy;Treatment noncompliance;Virologic failure,109835302,OT,,,109835302,1,201409,,,,109835302,1,Product used for unknown indication
10983928,109839282,2,F,2015,20150629,20150403,20150707,EXP,,US-GILEAD-2015-0145238,GILEAD,,48,YR,A,F,Y,,,20150707,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood creatinine increased;CD4 lymphocytes abnormal;Diabetes mellitus;Drug ineffective;Drug interaction;Drug resistance;HIV test positive;Hypertension;Pregnancy,109839282,OT,,,109839282,1,201501,,,,109839282,1,Product used for unknown indication
11002842,110028422,2,F,20150310,20150909,20150408,20150921,EXP,,BW-GILEAD-2015-0146397,GILEAD,,39,YR,A,M,Y,,,20150921,N,MD,BW,BW,EFAVIRENZ,VIIth nerve paralysis,110028422,HO,,,110028422,1,20091118,20150226,,,110028422,1,HIV infection
11060983,110609832,2,F,,20150806,20150424,20150807,EXP,,CA-ROCHE-1567419,ROCHE,,54,YR,,M,Y,,,20150807,N,OT,CA,CA,SUSTIVA,Depression;Drug interaction,110609832,OT,,,,,,,,,110609832,1,Product used for unknown indication
11071015,110710152,2,F,,20150806,20150428,20150810,EXP,,CA-ROCHE-1569262,ROCHE,,54,YR,,M,Y,,,20150810,N,CN,CA,CA,SUSTIVA,Depression;Drug interaction,110710152,OT,,,,,,,,,110710152,1,Product used for unknown indication
11073897,110738972,2,F,,20150806,20150429,20150810,EXP,,CA-ROCHE-1569238,ROCHE,,54,YR,,M,Y,,,20150810,N,CN,CA,CA,SUSTIVA,Depression;Drug interaction,110738972,OT,,,,,,,,,110738972,1,Product used for unknown indication
11090452,110904528,8,F,20140729,20150903,20150505,20150910,EXP,,ZA-GILEAD-2015-0151205,GILEAD,,35,YR,A,F,Y,,,20150910,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Dysmenorrhoea;Eosinophilia;Eye infection;Menorrhagia;Vaginal haemorrhage,110904528,OT,,,110904528,1,20140729,,,,110904528,1,HIV infection
11095483,110954832,2,F,,20150429,20150506,20150722,PER,,US-GILEAD-2015-0151603,GILEAD,,,,A,M,Y,,,20150722,N,CN,US,US,SUSTIVA,Dysphagia;Foreign body;Throat irritation,,,,,,,,,,,110954832,1,Product used for unknown indication
11105063,111050633,3,F,,20150415,20150511,20150722,PER,,US-GILEAD-2015-0153119,GILEAD,,27,YR,A,M,Y,,,20150722,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nausea,,,,,,,,,,,111050633,1,Product used for unknown indication
11110455,111104552,2,F,20150417,20150728,20150513,20150804,EXP,,BR-GILEAD-2015-0152958,GILEAD,,31,YR,A,M,Y,53.5,KG,20150804,N,MD,BR,BR,EFAVIRENZ,Abscess neck;Peritonsillar abscess,111104552,HO,,,111104552,1,20120106,,,,111104552,1,HIV infection
11111379,111113792,2,F,20150428,20150909,20150513,20150914,EXP,,UG-GILEAD-2015-0152101,GILEAD,,58,YR,A,M,Y,77,KG,20150914,N,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drowning,111113792,OT,,,111113792,1,20141208,20150427,,,111113792,1,HIV infection
11113560,111135602,2,F,,20150721,20150514,20150803,EXP,,US-CIPLA LTD.-2015FR03694,CIPLA,"JOANNA KRYST, PAWEL KAWALEC AND ANDRZEJ PILC. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL-NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015;1-23",,,,,Y,,,20150803,N,OT,PL,US,Efavirenz,Adverse event,111135602,OT,,,,,,,,,111135602,1,HIV infection
11130074,111300742,2,F,,20150515,20150521,20150723,PER,,US-GILEAD-2015-0154254,GILEAD,,39,YR,A,M,Y,,,20150723,N,MD,US,US,SUSTIVA,Diarrhoea;Headache;Hypoaesthesia;Nightmare;Pain;Speech disorder,,,,,111300742,1,20150505,20150513,,,111300742,1,Product used for unknown indication
11135923,111359234,4,F,20150119,20150728,20150526,20150731,EXP,,UG-GILEAD-2015-0154199,GILEAD,,37,YR,A,M,Y,,,20150731,N,MD,UG,UG,EFAVIRENZ,Acidosis;Acute kidney injury;Hepatitis acute;Subcutaneous abscess,111359234,LT,,,111359234,1,20150107,20150222,,,111359234,1,HIV infection
11142494,111424943,3,F,20140219,20150707,20150527,20150715,EXP,,KE-GILEAD-2015-0154204,GILEAD,,31,YR,A,M,Y,50.3,KG,20150715,N,MD,KE,KE,EFAVIRENZ,Peritoneal tuberculosis,111424943,HO,,,111424943,1,20140212,20140226,,,111424943,1,HIV infection
11151355,111513553,3,F,,20150430,20150601,20150828,PER,,US-JNJFOC-20150520630,JANSSEN,"CASTILLO JJ, REAGAN JL, SIKOV WM, WINER ES. BORTEZOMIB IN COMBINATION WITH INFUSIONAL DOSE-ADJUSTED EPOCH FOR THE TREATMENT OF PLASMABLASTIC LYMPHOMA. BRITISH JOURNAL OF HAEMATOLOGY 2015;169 (3):352-355.",40,YR,A,M,Y,,,20150828,N,MD,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL",Herpes zoster;Neuropathy peripheral;Thrombocytopenia;Treatment noncompliance,111513553,OT,,,,,,,,,111513553,1,Plasmablastic lymphoma
11152243,111522433,3,F,20140714,20150817,20150601,20150825,EXP,,ZA-GILEAD-2014-0111067,GILEAD,,46,YR,A,F,Y,64.9,KG,20150825,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,111522433,OT,,,111522433,1,20121213,20140706,,,111522433,1,HIV infection
11157011,111570112,2,F,20150309,20150714,20150602,20150717,EXP,,GB-BMSGILMSD-2015-0155123,GILEAD,,54,YR,A,M,Y,93,KG,20150717,N,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malignant melanoma,111570112,OT,,,111570112,1,201406,,,,111570112,1,HIV infection
11160250,111602502,2,F,,20150619,20150603,20150703,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-035890,BRISTOL MYERS SQUIBB,,38,YR,,M,Y,,,20150703,N,CN,US,US,EFAVIRENZ,Basedow's disease;Immune reconstitution inflammatory syndrome,111602502,OT,,,,,,,,,111602502,1,Antiretroviral therapy
11172159,111721592,2,F,,20150429,20150608,20150722,PER,,US-GILEAD-2015-0155231,GILEAD,,67,YR,E,M,Y,,,20150722,N,CN,US,US,SUSTIVA,Dysphagia;Foreign body;Product quality issue;Throat irritation,,,,,111721592,3,2014,,,,111721592,1,HIV infection
11200743,112007432,2,F,20141122,20150629,20150618,20150701,EXP,,UG-GILEAD-2015-0145451,GILEAD,,38,YR,A,F,Y,,,20150701,N,MD,UG,UG,EFAVIRENZ,Cytomegalovirus chorioretinitis;Death,112007432,DS,,,112007432,1,20141023,20150414,,,112007432,1,HIV infection
11202620,112026202,2,F,,20150803,20150619,20150817,EXP,,TN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-037940,BRISTOL MYERS SQUIBB,,37,YR,,M,Y,,,20150817,N,OT,TN,TN,EFAVIRENZ,Acute coronary syndrome,112026202,OT,,,112026202,1,2008,,,,112026202,1,HIV infection
11202890,112028902,2,F,,20150803,20150619,20150817,EXP,,TN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-040845,BRISTOL MYERS SQUIBB,,36,YR,,M,Y,,,20150817,N,OT,TN,TN,EFAVIRENZ,Acute coronary syndrome;Dyslipidaemia,112028902,OT,,,112028902,2,1997,,,,112028902,1,HIV infection
11217131,112171313,3,F,20150520,20150527,20150624,20150807,EXP,,BR-GILEAD-2015-0156278,GILEAD,,47,YR,A,M,Y,,,20150807,N,MD,BR,BR,EFAVIRENZ,Decreased appetite;Dehydration;Disseminated tuberculosis;Dysphagia;Hypoaesthesia;Pyrexia,112171313,HO,,,112171313,1,20150513,20150521,,,112171313,1,HIV infection
11229774,112297742,2,F,20150423,20150805,20150630,20150811,EXP,,US-BMSGILMSD-2015-0160600,GILEAD,,48,YR,A,M,Y,,,20150811,N,MD,US,US,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alcohol poisoning;Death;Pneumonia;Spinal fracture,112297742,HO,,,112297742,1,20150416,20150424,,,112297742,1,HIV infection
11232764,112327643,3,F,20150519,20150818,20150701,20150825,EXP,,ZA-GILEAD-2015-0159824,GILEAD,,32,YR,A,F,Y,114.8,KG,20150825,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Adenocarcinoma;Metastases to liver,112327643,HO,,,112327643,1,20111024,,,,112327643,1,HIV infection
11234093,112340931,1,I,,20150622,20150702,20150702,EXP,,US-CIPLA LTD.-2015US05088,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150702,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Laryngeal pain,112340931,OT,,,,,,,,,112340931,1,HIV infection
11234094,112340941,1,I,,20150622,20150702,20150702,EXP,,US-CIPLA LTD.-2015US05107,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150702,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz,Virologic failure,112340941,OT,,,,,,,,,112340941,1,HIV infection
11234095,112340951,1,I,,20150622,20150702,20150702,EXP,,US-CIPLA LTD.-2015US05103,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150702,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Virologic failure,112340951,OT,,,,,,,,,112340951,1,HIV infection
11234440,112344401,1,I,,20150622,20150702,20150702,EXP,,US-CIPLA LTD.-2015US05106,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150702,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz,Virologic failure,112344401,OT,,,,,,,,,112344401,1,HIV infection
11234441,112344411,1,I,,20150622,20150702,20150702,EXP,,US-CIPLA LTD.-2015US05104,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150702,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Creatinine renal clearance decreased,112344411,OT,,,,,,,,,112344411,1,HIV infection
11235047,112350471,1,I,,20150325,20150702,20150702,EXP,,US-BMSGILMSD-2015-0145407,GILEAD,,32,YR,A,M,Y,,,20150702,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,CD4 lymphocytes abnormal;Drug ineffective;Drug resistance;HIV test positive;Virologic failure,112350471,OT,,,112350471,1,201412,,,,112350471,1,HIV infection
11235165,112351652,2,F,20150522,20150624,20150702,20150709,EXP,,PE-GILEAD-2015-0161248,GILEAD,,41,YR,A,M,Y,69.5,KG,20150709,N,MD,PE,PE,EFAVIRENZ,Chronic hepatitis B,112351652,OT,,,112351652,1,20150227,20150521,,,112351652,1,HIV infection
11235638,112356381,1,I,20140124,20150626,20150702,20150702,EXP,,ZW-GILEAD-2015-0160757,GILEAD,,46,YR,A,M,Y,,,20150702,N,MD,ZW,ZW,EFAVIRENZ,Gastroenteritis,112356381,HO,,,112356381,1,20140116,20140128,,,112356381,1,HIV infection
11237694,112376941,1,I,,20150622,20150703,20150703,EXP,,US-CIPLA LTD.-2015US05114,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150703,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Pancreatitis acute,112376941,OT,,,,,,,,,112376941,1,HIV infection
11237696,112376961,1,I,,20150622,20150703,20150703,EXP,,US-CIPLA LTD.-2015US05112,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150703,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Hepatitis acute,112376961,OT,,,,,,,,,112376961,1,HIV infection
11237697,112376971,1,I,,20150622,20150703,20150703,EXP,,US-CIPLA LTD.-2015US05115,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150703,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Virologic failure,112376971,OT,,,,,,,,,112376971,1,HIV infection
11237701,112377011,1,I,,20150622,20150703,20150703,EXP,,US-CIPLA LTD.-2015US05116,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150703,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Virologic failure,112377011,OT,,,,,,,,,112377011,1,HIV infection
11238562,112385623,3,F,20150528,20150917,20150706,20150923,EXP,,FR-GILEAD-2015-0160731,GILEAD,,45,YR,A,M,Y,65,KG,20150923,N,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cholecystitis,112385623,HO,,,112385623,1,20100605,,,,112385623,1,HIV infection
11238812,112388121,1,I,,20150608,20150706,20150706,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-038383,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20150706,N,OT,US,US,SUSTIVA,Wrong technique in product usage process,,,,,,,,,,,112388121,1,HIV infection
11239685,112396853,3,F,20150624,20150731,20150706,20150807,PER,,ZA-JNJFOC-20150623648,JANSSEN,,34,YR,A,M,Y,42.5,KG,20150807,N,OT,ZA,ZA,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL",Disseminated tuberculosis;Pulmonary tuberculosis,112396853,OT,,,112396853,1,20150522,20150625,,,112396853,1,Pulmonary tuberculosis
11242027,112420271,1,I,,20150325,20150706,20150706,EXP,,US-BMSGILMSD-2015-0145612,GILEAD,,26,YR,A,M,Y,,,20150706,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,CD4 lymphocytes abnormal;Drug ineffective;Drug resistance,112420271,OT,,,112420271,1,201403,,,,112420271,1,Product used for unknown indication
11242430,112424302,2,F,20150522,20150714,20150707,20150813,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-042462,BRISTOL MYERS SQUIBB,,41,YR,,M,Y,70,KG,20150813,N,OT,PE,PE,EFAVIRENZ,Alanine aminotransferase increased;Chronic hepatitis B,112424302,LT,,,112424302,1,20150227,,,,112424302,1,HIV infection
11245634,112456341,1,I,,20150629,20150707,20150707,EXP,,US-BMSGILMSD-2015-0161097,GILEAD,,59,YR,A,M,Y,,,20150707,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Tuberculosis,112456341,OT,,,,,,,,,112456341,1,HIV infection
11246468,112464681,1,I,,20150626,20150708,20150708,EXP,,TH-CIPLA LTD.-2015TH05396,CIPLA,"LINDA AURPIBUL, TIM R. CRESSEY, SIRINTIP SRICHAROENCHAI, ORASRI WITTAWATMONGKOL, VIRAT SIRISANTHANA, WANATPREEYA PHONGSAMART ET AL. EFFICACY, SAFETY AND PHARMACOKINETICS OF TENOFOVIR DISOPROXIL FUMARATE IN VIROLOGIC-SUPPRESSED HIV-INFECTED CHILDREN USING WEIGHT-BAND DOSING. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2015;34:392-397",,,,,Y,,,20150708,N,OT,TH,TH,Efavirenz,Tonsillitis,112464681,HO,,,,,,,,,112464681,1,HIV infection
11246497,112464971,1,I,,20150626,20150708,20150708,EXP,,TH-CIPLA LTD.-2015TH05400,CIPLA,"LINDA AURPIBUL, TIM R. CRESSEY, SIRINTIP SRICHAROENCHAI, ORASRI WITTAWATMONGKOL, VIRAT SIRISANTHANA, WANATPREEYA PHONGSAMART ET AL. EFFICACY, SAFETY AND PHARMACOKINETICS OF TENOFOVIR DISOPROXIL FUMARATE IN VIROLOGIC-SUPPRESSED HIV-INFECTED CHILDREN USING WEIGHT-BAND DOSING. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2015;34:392-397",,,,,Y,,,20150708,N,OT,TH,TH,Efavirenz,Ventriculo-peritoneal shunt,112464971,HO,,,,,,,,,112464971,1,HIV infection
11246498,112464981,1,I,,20150626,20150708,20150708,EXP,,TH-CIPLA LTD.-2015TH05398,CIPLA,"LINDA AURPIBUL, TIM R. CRESSEY, SIRINTIP SRICHAROENCHAI, ORASRI WITTAWATMONGKOL, VIRAT SIRISANTHANA, WANATPREEYA PHONGSAMART ET AL. EFFICACY, SAFETY AND PHARMACOKINETICS OF TENOFOVIR DISOPROXIL FUMARATE IN VIROLOGIC-SUPPRESSED HIV-INFECTED CHILDREN USING WEIGHT-BAND DOSING. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2015;34:392-397",,,,,Y,,,20150708,N,OT,TH,TH,Efavirenz,Influenza,112464981,HO,,,,,,,,,112464981,1,HIV infection
11246510,112465101,1,I,,20150626,20150708,20150708,EXP,,US-CIPLA LTD.-2015US05463,CIPLA,"SAEZ-LLORENS X, CASTANO E, RATHORE M, CHURCH J, DEVILLE J, GAUR A, RHEE.M.ET.AL. A RANDOMIZED, OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF SWITCHING STAVUDINE OR ZIDOVUDINE TO TENOFOVIR DISOPROXIL FUMARATE IN HIV-1-INFECTED CHILDREN WITH VIROLOGIC SUPPRESSION. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2015;34:376-382",,,,,Y,,,20150708,N,OT,US,US,Efavirenz,Bronchitis,112465101,OT,,,,,,,,,112465101,1,HIV infection
11246512,112465121,1,I,,20150626,20150708,20150708,EXP,,US-CIPLA LTD.-2015US05465,CIPLA,"SAEZ-LLORENS X, CASTANO E, RATHORE M, CHURCH J, DEVILLE J, GAUR A, RHEE.M.ET.AL. A RANDOMIZED, OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF SWITCHING STAVUDINE OR ZIDOVUDINE TO TENOFOVIR DISOPROXIL FUMARATE IN HIV-1-INFECTED. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2015;34:376-382",,,,,Y,,,20150708,N,OT,US,US,Efavirenz,Brain neoplasm,112465121,OT,,,,,,,,,112465121,1,HIV infection
11247552,112475521,1,I,,20150625,20150706,20150706,EXP,,KZ2015GSK091882,VIIV,,9,YR,,M,N,,,20150702,N,MD,KZ,,STOCRIN (EFAVIRENZ),Agranulocytosis;Aplastic anaemia;Asthenia;Dermatitis;Developmental delay;Fatigue;Hepatitis toxic;Hypotonia;Lymphadenitis;Mitral valve prolapse;Odynophagia;Oropharyngeal candidiasis,112475521,HO,112475521,HP,112475521,1,20150113,20150105,,,112475521,1,HIV infection
11248890,112488901,1,I,,20140804,20150708,20150708,EXP,,AU-CIPLA LTD.-2014AU01135,CIPLA,"DIANNE CAREY. EFFICACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS 2015. 2015;15:793-802",,,,,Y,,,20150708,N,OT,AU,AU,Efavirenz,Completed suicide,112488901,DE,,,,,,,,,112488901,1,HIV infection
11248891,112488911,1,I,,20140804,20150708,20150708,EXP,,AU-CIPLA LTD.-2014AU01134,CIPLA,"DIANNE CAREY. EFFICACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS 2015. 2005;15:793-802",,,,,Y,,,20150708,N,OT,AU,AU,Efavirenz,Pneumonia bacterial,112488911,DE,,,,,,,,,112488911,1,HIV infection
11255828,112558282,2,F,20150415,20150908,20150709,20150915,EXP,,KE-GILEAD-2015-0161643,GILEAD,,43,YR,A,F,Y,67.9,KG,20150915,N,MD,KE,KE,EFAVIRENZ,Acute kidney injury;Blood creatinine increased;Hyperkalaemia,112558282,OT,,,112558282,1,20150318,20150416,,,112558282,1,Product used for unknown indication
11256152,112561521,1,I,,20141002,20150709,20150709,EXP,,US-VIIV HEALTHCARE LIMITED-US2014GSK017827,VIIV,,,,,M,Y,,,20150709,N,OT,US,US,SUSTIVA,Diarrhoea,,,,,112561521,1,201207,201411,,,112561521,1,HIV infection
11256159,112561591,1,I,2012,20150116,20150709,20150709,EXP,,US-VIIV HEALTHCARE LIMITED-US2015005970,VIIV,,,,,M,Y,,,20150709,N,CN,COUNTRY NOT SPECIFIED,US,SUSTIVA,Visual acuity reduced,,,,,112561591,1,2011,,,,112561591,1,HIV infection
11258139,112581391,1,I,20150623,20150625,20150710,20150710,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-043114,BRISTOL MYERS SQUIBB,,33,YR,,M,Y,49,KG,20150710,N,OT,MW,MW,EFAVIRENZ,Kaposi's sarcoma,112581391,OT,,,112581391,1,20150311,20150610,,,112581391,1,Antiretroviral therapy
11258240,112582401,1,I,,20150702,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05579,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710,N,OT,AU,AU,Efavirenz,Pancreatic carcinoma,112582401,DE,,,,,,,,,112582401,1,HIV infection
11258258,112582581,1,I,,20150702,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05577,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710,N,OT,AU,AU,Efavirenz,Suicide attempt,112582581,OT,,,,,,,,,112582581,1,HIV infection
11258260,112582601,1,I,,20150702,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05576,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710,N,OT,AU,AU,Efavirenz,Oedema genital;Rash,112582601,OT,,,,,,,,,112582601,1,HIV infection
11258262,112582621,1,I,,20150702,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05578,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710,N,OT,AU,AU,Efavirenz,Stab wound,112582621,DE,,,,,,,,,112582621,1,HIV infection
11258263,112582631,1,I,,20150702,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05598,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710,N,OT,AU,AU,Efavirenz,Acute myocardial infarction,112582631,DE,,,,,,,,,112582631,1,HIV infection
11258264,112582641,1,I,,20150702,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05582,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710,N,OT,AU,AU,Efavirenz,Adverse drug reaction;Septic shock,112582641,DE,,,,,,,,,112582641,1,HIV infection
11258272,112582721,1,I,,20150702,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05599,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710,N,OT,AU,AU,Efavirenz,Maternal death during childbirth,112582721,DE,,,,,,,,,112582721,1,HIV infection
11258280,112582801,1,I,,20150702,20150710,20150710,EXP,,AU-CIPLA LTD.-2015AU05601,CIPLA,"DR DIANNE CAREY. EFFI CACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793 TO 802",,,,,Y,,,20150710,N,OT,AU,AU,Efavirenz,Gun shot wound,112582801,DE,,,,,,,,,112582801,1,HIV infection
11258293,112582931,1,I,,20140804,20150710,20150710,EXP,,AU-CIPLA LTD.-2014AU01133,CIPLA,"DIANNE CAREY, REBEKAH PULS, JANAKI AMIN, MARCELO LOSSO, PRAPHAN PHANUPAK, SHARNE FOULKES, LERATO MOHAPI ET AL. EFFICACY AND SAFETY OF EFAVIRENZ 400 MG DAILY VERSUS 600 MG DAILY: 96-WEEK DATA FROM THE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, NON-INFERIORITY ENCORE1 STUDY. LANCET INFECT DIS. 2015;15:793-802",,,,,Y,,,20150710,N,MD,AU,AU,Efavirenz,Septic shock,112582931,DE,,,,,,,,,112582931,1,HIV infection
11258366,112583662,2,F,20090428,20150710,20150710,20150717,EXP,,BR-VIIV HEALTHCARE LIMITED-B0581303A,VIIV,,31,YR,,F,Y,58,KG,20150717,N,MD,BR,BR,Efavirenz,Decreased appetite;Depressed mood;Depression;Fatigue;Homicidal ideation;Loss of libido;Suicidal ideation;Terminal insomnia;Violence-related symptom,112583662,LT,,,112583662,1,20080416,20090701,,,112583662,1,Prophylaxis against HIV infection
11271273,112712731,1,I,,20150703,20150714,20150714,EXP,,PHHY2015IN081662,SANDOZ,"THAKUR BK, VERMA S, MISHRA J. LICHENOID DRUG REACTION TO ISONIAZID PRESENTING AS EXFOLIATIVE DERMATITIS IN A PATIENT WITH ACQUIRED IMMUNODEFICIENCY SYNDROME. INT-J-STD-AIDS. 2015;26(7):512-15",31,YR,,M,Y,,,20150714,N,OT,IN,IN,EFAVIRENZ,Dermatitis exfoliative;Exfoliative rash;Lichenoid keratosis;Papule;Skin exfoliation,112712731,OT,,,,,,,,,112712731,1,Pulmonary tuberculosis
11273970,112739702,2,F,20150123,20150903,20150715,20150910,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-045344,BRISTOL MYERS SQUIBB,,40,YR,,M,Y,,,20150910,N,OT,UG,UG,EFAVIRENZ,Hepatic failure;Oral candidiasis;Pulmonary tuberculosis,112739702,LT,,,112739702,1,20150121,20150407,,,112739702,1,HIV infection
11274333,112743332,2,F,2015,20150724,20150715,20150730,EXP,,US-GILEAD-2015-0161669,GILEAD,,,,,M,Y,,,20150730,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal death;Foetal megacystis,112743332,DE,,,112743332,1,20150320,20150519,,,112743332,1,HIV infection
11276482,112764821,1,I,,20150706,20150716,20150716,EXP,,CH-CIPLA LTD.-2015CH05637,CIPLA,"LAURA C, CAVASSINI M, GENNE D, DELHUMEAU C, ELBES R.S, HILL A.ET.AL. SWITCH TO ETRAVIRINE FOR HIV-POSITIVE PATIENTS RECEIVING STATIN TREATMENT: A PROSPECTIVE STUDY. EUR J CLIN INVEST. 2015;45 (7):720-730",,,,,Y,,,20150716,N,OT,CH,CH,Efavirenz,Acute kidney injury,112764821,OT,,,,,,,,,112764821,1,HIV infection
11277591,112775911,1,I,,20150709,20150716,20150716,EXP,,ZA-GILEAD-2015-0162987,GILEAD,BARNARDT P AND RELLING M. GESTATIONAL TROPHOBLASTIC NEOPLASM AND WOMEN LIVING WITH HIV AND/OR AIDS. S AFR J HIV MED.. 2015;16(1):UNK,33,YR,A,F,Y,,,20150716,N,OT,ZA,ZA,EFAVIRENZ,Abortion spontaneous,112775911,OT,,,,,,,,,112775911,1,Acquired immunodeficiency syndrome
11277775,112777751,1,I,,20150709,20150716,20150716,EXP,,US-BMSGILMSD-2015-0163015,GILEAD,,,,,M,Y,,,20150716,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Amino acid level decreased;Staphylococcal infection,112777751,HO,,,,,,,,,112777751,1,HIV infection
11282210,112822101,1,I,20140922,20150707,20150720,20150720,EXP,,KE-CIPLA LTD.-2015KE05833,CIPLA,,,,,,Y,,,20150720,N,OT,US,KE,Efavirenz,Abortion spontaneous;Exposure during pregnancy,112822101,OT,,,112822101,1,20131014,,,,112822101,1,HIV infection
11283749,112837491,1,I,,20150715,20150720,20150720,EXP,,US-VIIV HEALTHCARE LIMITED-US2015102836,VIIV,,,,,M,Y,,,20150720,N,CN,US,US,SUSTIVA,Viral load,,,,,,,,,,,112837491,1,HIV infection
11285494,112854941,1,I,20150308,20150714,20150720,20150720,EXP,,CL-GILEAD-2015-0163516,GILEAD,,29,YR,A,M,Y,78,KG,20150720,N,MD,CL,CL,EFAVIRENZ,Cholecystitis acute,112854941,HO,,,112854941,1,20130226,,,,112854941,1,HIV infection
11285522,112855221,1,I,20150614,20150713,20150720,20150720,EXP,,UG-GILEAD-2015-0163190,GILEAD,,39,YR,A,M,Y,,,20150720,N,OT,UG,UG,EFAVIRENZ,Kaposi's sarcoma,112855221,LT,,,112855221,1,20150128,,,,112855221,1,HIV infection
11289331,112893311,1,I,20141003,20150707,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024153,MYLAN,,,,,,Y,,,20150721,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,112893311,OT,,,112893311,1,20130313,,,,112893311,1,HIV infection
11289334,112893341,1,I,,20150707,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024158,MYLAN,,,,,,Y,,,20150721,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Cleft lip and palate;Foetal exposure during pregnancy;Maternal drugs affecting foetus,112893341,OT,,,,,,,,,112893341,1,HIV infection
11289347,112893471,1,I,20140812,20150707,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024140,MYLAN,,,,,,Y,,,20150721,N,OT,KE,KE,EFAVIRENZ W/LAMIVUDINE/STAVUDINE,Abortion spontaneous;Exposure during pregnancy,112893471,OT,,,112893471,1,20140313,,,,112893471,1,HIV infection
11289348,112893481,1,I,20141006,20150707,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024148,MYLAN,,,,,,Y,,,20150721,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,112893481,OT,,,112893481,1,20140411,,,,112893481,1,HIV infection
11289358,112893581,1,I,20140526,20150707,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024154,MYLAN,,,,,,Y,,,20150721,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,112893581,OT,,,112893581,1,20130213,,,,112893581,1,HIV infection
11289359,112893591,1,I,20140922,20150707,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024155,MYLAN,,,,,,Y,,,20150721,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,112893591,OT,,,112893591,1,20131029,,,,112893591,1,HIV infection
11289360,112893601,1,I,20140926,20150707,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024157,MYLAN,,,,,,Y,,,20150721,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,112893601,OT,,,112893601,1,20131113,,,,112893601,1,HIV infection
11289961,112899611,1,I,20150608,20150714,20150721,20150721,EXP,,US-GILEAD-2015-0163480,GILEAD,,53,YR,A,M,Y,115.9,KG,20150721,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute myocardial infarction,112899611,OT,,,112899611,1,20110107,,,,112899611,1,HIV infection
11290164,112901641,1,I,2015,20150717,20150721,20150721,EXP,,US-BMSGILMSD-2015-0164176,GILEAD,,60,YR,A,M,Y,,,20150721,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Spinal fracture,112901641,OT,,,,,,,,,112901641,1,HIV infection
11290406,112904061,1,I,20140617,20150707,20150722,20150722,EXP,,KE-MYLANLABS-2015M1024156,MYLAN,,,,,,Y,,,20150722,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Foetal exposure during pregnancy;Maternal drugs affecting foetus;Stillbirth,112904061,DE,,,112904061,1,20130109,,,,112904061,1,HIV infection
11307217,113072171,1,I,20150219,20150716,20150723,20150723,EXP,,ZA-BMSGILMSD-2015-0164444,GILEAD,,,,N,,Y,,,20150723,N,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hypoplastic nasal cartilage;Limb reduction defect,113072171,OT,,,113072171,1,20150219,,,,113072171,1,HIV infection
11308119,113081191,1,I,,20150715,20150724,20150724,EXP,,ES-CIPLA LTD.-2015ES05927,CIPLA,"CASADO JL, MARIN A, ROMERO V, BANON S, MORENO A, PEREZ-ELIAS MJ.ET.AL. THE INFLUENCE OF PATIENT BELIEFS AND TREATMENT SATISFACTION ON THE DISCONTINUATION OF CURRENT FIRST-LINE ANTIRETROVIRAL REGIMENS. HIV MEDICINE. 2015;1-10",,,,,Y,,,20150724,N,OT,ES,ES,Efavirenz,Jaundice,113081191,OT,,,,,,,,,113081191,1,HIV infection
11308120,113081201,1,I,,20150715,20150724,20150724,EXP,,ES-CIPLA LTD.-2015ES05929,CIPLA,"CASADO JL, MARIN A, ROMERO V, BANON S, MORENO A, PEREZ-ELIAS MJ.ET.AL. THE INFLUENCE OF PATIENT BELIEFS AND TREATMENT SATISFACTION ON THE DISCONTINUATION OF CURRENT FIRST-LINE ANTIRETROVIRAL REGIMENS. HIV MEDICINE. 2015;1-10",,,,,Y,,,20150724,N,OT,ES,ES,Efavirenz,Nephropathy toxic,113081201,OT,,,,,,,,,113081201,1,HIV infection
11308123,113081231,1,I,,20150715,20150724,20150724,EXP,,ES-CIPLA LTD.-2015ES05931,CIPLA,"CASADO JL, MARIN A, ROMERO V, BANON S, MORENO A, PEREZ-ELIAS MJ.ET.AL. THE INFLUENCE OF PATIENT BELIEFS AND TREATMENT SATISFACTION ON THE DISCONTINUATION OF CURRENT FIRST-LINE ANTIRETROVIRAL REGIMENS. HIV MEDICINE. 2015;1-10",,,,,Y,,,20150724,N,OT,ES,ES,Efavirenz,Drug interaction,113081231,OT,,,,,,,,,113081231,1,HIV infection
11309489,113094891,1,I,,20150715,20150724,20150724,EXP,,LS-GLAXOSMITHKLINE INC.-LS2015GSK105502,GLAXOSMITHKLINE,"SATTI H, MCLAUGHLIN MM, SEUNG KJ.. SHORT REPORT: DRUG-RESISTANT TUBERCULOSIS TREATMENT COMPLICATED BY ANTIRETROVIRAL. AM. J. TROP. MED. HYG. 2013;89 (1):174-177",59,YR,,M,Y,,,20150724,N,OT,LS,LS,Efavirenz,CD4 lymphocytes decreased;Drug resistance;Viral mutation identified,113094891,DE,,,,,,,,,113094891,1,HIV infection
11309589,113095891,1,I,,20150715,20150724,20150724,EXP,,LS-VIIV HEALTHCARE LIMITED-LS2015GSK105502,VIIV,"SATTI H, MCLAUGHLIN MM, SEUNG KJ.. SHORT REPORT: DRUG-RESISTANT TUBERCULOSIS TREATMENT COMPLICATED BY ANTIRETROVIRAL. AM. J. TROP. MED. HYG. 2013;89 (1):174-177",59,YR,,M,Y,,,20150724,N,OT,LS,LS,Efavirenz,CD4 lymphocytes decreased;Drug resistance;Viral mutation identified,113095891,DE,,,,,,,,,113095891,1,HIV infection
11314307,113143071,1,I,20140823,20140617,20150727,20150727,EXP,,RU-VIIV HEALTHCARE LIMITED-B1006356A,VIIV,,,,,M,Y,,,20150727,N,CN,RU,RU,EFAVIRENZ,Asthenia;Chest pain;Chronic gastritis;Duodenitis;Erosive oesophagitis;Gastric disorder;Gastric polyps;Gastritis haemorrhagic;Gastrooesophageal reflux disease;Head discomfort;Headache;Hiatus hernia;Hyperchlorhydria;Influenza like illness;Initial insomnia;Irritability;Lymph node pain;Musculoskeletal discomfort;Nail discolouration;Nasal obstruction;Nasopharyngitis;Nervousness;Neurosis;Oropharyngeal pain;Pharyngeal disorder;Pharyngeal erosion;Pharyngeal erythema;Pharyngitis;Pyrexia;Respiratory tract infection viral;Rhinorrhoea;Tongue coated;Tonsillar inflammation,113143071,OT,,,113143071,1,201312,,,,113143071,1,HIV infection
11314312,113143121,1,I,2011,20150720,20150727,20150727,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2015GSK104295,VIIV,,,,,M,Y,,,20150727,N,CN,RU,RU,STOCRIN (EFAVIRENZ),Aggression;Depression;Disturbance in attention;Encephalopathy;Headache;Memory impairment;Mood swings;Social avoidant behaviour,113143121,OT,,,113143121,1,2011,,,,113143121,1,HIV infection
11315198,113151981,1,I,,20150721,20150727,20150727,EXP,,US-BMSGILMSD-2015-0164539,GILEAD,,,,,M,Y,,,20150727,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Brain injury;Road traffic accident,113151981,OT,,,,,,,,,113151981,1,HIV infection
11316088,113160881,1,I,,20150709,20150724,20150724,EXP,,2015HINCT0590,HETERO,,,,,F,N,,,20150722,N,MD,KE,,"EFAVIRENZ+LAMIVUDINE+TENOFOVIR (EFAVIRENZ, LAMIVUDINE, TENOFIVIR)",Abortion spontaneous;Contraindicated drug administered;Maternal exposure during pregnancy;Pregnancy,113160881,OT,113160881,FGN,113160881,1,20131029,,,,113160881,1,HIV infection
11316102,113161021,1,I,,20150709,20150724,20150724,EXP,,2015HINCT0591,HETERO,,,,,F,N,,,20150722,N,MD,KE,,"EFAVIRENZ+LAMIVUDINE+TENOFOVIR (EFAVIRENZ, LAMIVUDINE, TENOFOVIR) UNKNOWN",Abortion spontaneous;Contraindicated drug administered;Maternal exposure during pregnancy;Pregnancy,113161021,OT,113161021,HP,113161021,1,20131113,,,,113161021,1,HIV infection
11316227,113162271,1,I,,20150709,20150724,20150724,EXP,,2015HINCT0621,HETERO,,,,,M,N,,,20150722,N,MD,KE,,"EFAVIRENZ+LAMIVUDINE+TENOFOVIR(EFAVIRENZ, LAMIVUDINE, TENOFOVIR) UNKNOWN",Cleft lip and palate;Foetal exposure during pregnancy;Live birth;Maternal drugs affecting foetus;Premature baby,113162271,CA,113162271,FGN,113162271,1,20140307,,,,113162271,1,Maternal exposure during pregnancy
11316346,113163461,1,I,,20150709,20150724,20150724,EXP,,2015HINCT0599,HETERO,,,,,F,N,,,20150722,N,MD,KE,,"EFAVIRENZ+LAMIVUDINE+TENOFOVIR (EFAVIRENZ, LAMIVUDINE, TENOFOVIR) UNKNOWN",Contraindicated drug administered;Maternal exposure during pregnancy;Pregnancy;Stillbirth,113163461,OT,113163461,FGN,113163461,1,20130109,,,,113163461,1,HIV infection
11316382,113163821,1,I,,20150709,20150724,20150724,EXP,,2015HINCT0601,HETERO,,,,,F,N,,,20150722,N,MD,KE,,LAMIVUDINE+STAVUDINE+EFAVIRENZ (LAMIVUDINE+STAVUDINE+EFAVIRENZ),Abortion spontaneous;Maternal exposure during pregnancy,113163821,OT,113163821,HP,113163821,1,20140313,,,,113163821,1,HIV infection
11316440,113164401,1,I,,20150720,20150728,20150728,EXP,,CA-ABBVIE-15P-028-1431693-00,ABBVIE,,,,,M,Y,,,20150728,N,OT,CA,CA,SUSTIVA,Depression;Drug interaction,113164401,OT,,,,,,,,,113164401,1,Product used for unknown indication
11316588,113165881,1,I,,20150709,20150724,20150724,EXP,,2015HINCT0612,HETERO,,,,,F,N,,,20150722,N,MD,KE,,"EFAVIRENZ+LAMIVUDINE+TENOFOVIR (EFAVIRENZ, LAMIVUDINE, TENOFOVIR) UNKNOWN",Abortion spontaneous;Maternal exposure during pregnancy,113165881,OT,113165881,FGN,113165881,1,20130213,,,,113165881,1,HIV infection
11316596,113165961,1,I,,20150709,20150724,20150724,EXP,,2015HINCT0613,HETERO,,,,,F,N,,,20150722,N,MD,KE,,"EFAVIRENZ + LAMIVUDINE + TENOFOVIR (EFAVIRENZ, LAMIVUDINE, TENOFOVIR)",Abortion spontaneous;Maternal exposure during pregnancy,113165961,OT,113165961,FGN,113165961,1,20140411,,,,113165961,1,HIV infection
11316613,113166131,1,I,,20150709,20150724,20150724,EXP,,2015HINCT0614,HETERO,,,,,F,N,,,20150722,N,MD,KE,,"EFAVIRENZ+LAMIVUDINE+TENOFOVIR (EFAVIRENZ, LAMIVUDINE, TENOFOVIR) UNKNOWN",Abortion spontaneous;Maternal exposure during pregnancy,113166131,OT,113166131,FGN,113166131,1,20150313,,,,113166131,1,HIV infection
11318040,113180401,1,I,,20150720,20150728,20150728,EXP,,CA-ABBVIE-15P-028-1431127-00,ABBVIE,,54,YR,,M,Y,,,20150728,N,CN,CA,CA,EFAVIRENZ,Depression;Drug interaction,113180401,OT,,,,,,,,,113180401,1,Product used for unknown indication
11318133,113181331,1,I,,20150720,20150728,20150728,EXP,,CA-ABBVIE-15P-028-1431684-00,ABBVIE,,84,YR,,M,Y,,,20150728,N,OT,CA,CA,SUSTIVA,Depression;Drug interaction,113181331,OT,,,,,,,,,113181331,1,Product used for unknown indication
11318157,113181571,1,I,,20150720,20150728,20150728,EXP,,CA-ABBVIE-15P-028-1431692-00,ABBVIE,,54,YR,,M,Y,,,20150728,N,OT,CA,CA,SUSTIVA,Depression;Drug interaction,113181571,OT,,,,,,,,,113181571,1,Product used for unknown indication
11318178,113181781,1,I,,20150720,20150728,20150728,EXP,,CA-ABBVIE-15P-028-1431123-00,ABBVIE,,54,YR,,M,Y,,,20150728,N,CN,CA,CA,SUSTIVA,Depression;Drug interaction,113181781,OT,,,,,,,,,113181781,1,Product used for unknown indication
11321780,113217802,2,F,,20150727,20150729,20150805,EXP,,US-BMSGILMSD-2015-0165282,GILEAD,,50,YR,A,M,Y,,,20150805,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Road traffic accident,113217802,HO,,,,,,,,,113217802,1,HIV infection
11322068,113220681,1,I,,20080124,20150729,20150729,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2008-000001,BRISTOL MYERS SQUIBB,,1,DY,,,Y,,,20150729,N,CN,GB,GB,EFAVIRENZ,Cardiac malposition;Congenital diaphragmatic anomaly;Congenital hepatobiliary anomaly;Deformity thorax;Diaphragmatic aplasia;Exomphalos;Foetal exposure during pregnancy;Microcephaly;Pneumothorax,113220681,OT,,,113220681,1,20070716,20070816,,,113220681,1,Product used for unknown indication
11322175,113221751,1,I,20141105,20150722,20150729,20150729,EXP,,HT-GILEAD-2015-0164906,GILEAD,,30,YR,A,F,Y,,,20150729,N,MD,HT,HT,EFAVIRENZ,Abortion spontaneous,113221751,OT,,,113221751,1,20140918,20140922,,,113221751,1,HIV infection
11322615,113226152,2,F,,20150720,20150730,20150804,EXP,,ZA-CIPLA LTD.-2015ZA06047,CIPLA,"ANNE DERACHE, CAROLE L. WALLIS, SARAN VARDHANABHUTI, JOHN BARTLETT, NAGALINGESWARAN KUMARASAMY, DAVID KATZENSTEIN. PHENOTYPE, GENOTYPE AND DRUG RESISTANCE IN SUBTYPE C HIV-1 INFECTION. 1 TO 26",,,,,Y,,,20150804,N,OT,ZA,ZA,Efavirenz,Drug resistance;Gene mutation;Treatment failure,113226152,OT,,,,,,,,,113226152,1,HIV infection
11323467,113234674,4,F,,20131024,20150730,20150731,EXP,,ZA-GILEAD-2013-0085742,VIIV,"FRIEDLAND G, NAIDOO P, ABDOOL-GAFOOR B, MOOSA M-Y, RAMDIAL P, GANDHI R. CASE 29-2013: A 32-YEAR-OLD HIV-POSITIVE AFRICAN MAN WITH DYSPNEA AND SKIN LESIONS. THE NEW ENGLAND JOURNAL OF MEDICINE. 2013;369:1152-1161",32,YR,,M,Y,,,20150731,N,MD,ZA,ZA,Efavirenz,Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma,113234674,HO,,,,,,,,,,,
11323509,113235094,4,F,,20150720,20150730,20150812,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-049213,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20150812,N,CN,US,US,SUSTIVA,Dizziness,,,,,,,,,,,113235094,1,Product used for unknown indication
11323514,113235141,1,I,,20130611,20150730,20150730,EXP,,KH-GLAXOSMITHKLINE-B0901849A,GLAXOSMITHKLINE,"OUK V ET AL. THE ADVANTAGE OF VIRAL LOAD IN PREVENTION FROM MOTHER TO CHILD TRANSMISSION. ABSTRACT PRESENTED AT THE 2013 CONFERENCE ON 30 YEARS OF HIV SCIENCE: IMAGINE THE FUTURE, 2013, PARIS, FRANCE:99.",,,,F,Y,,,20150730,N,MD,KH,KH,Efavirenz,Abortion spontaneous;Exposure during pregnancy,113235141,OT,,,,,,,,,113235141,2,HIV infection
11323541,113235411,1,I,,20130611,20150730,20150730,EXP,,KH-VIIV HEALTHCARE LIMITED-B0901851A,VIIV,"OUK V ET AL. THE ADVANTAGE OF VIRAL LOAD IN PREVENTION FROM MOTHER TO CHILD TRANSMISSION. ABSTRACT PRESENTED AT THE 2013 CONFERENCE ON 30 YEARS OF HIV SCIENCE: IMAGINE THE FUTURE, 2013, PARIS, FRANCE:99.",,,,F,Y,,,20150730,N,MD,KH,KH,Efavirenz,Abortion induced;Exposure during pregnancy,113235411,OT,,,,,,,,,113235411,1,HIV infection
11323548,113235481,1,I,,20130611,20150730,20150730,EXP,,KH-VIIV HEALTHCARE LIMITED-B0901849A,VIIV,"OUK V ET AL. THE ADVANTAGE OF VIRAL LOAD IN PREVENTION FROM MOTHER TO CHILD TRANSMISSION. ABSTRACT PRESENTED AT THE 2013 CONFERENCE ON 30 YEARS OF HIV SCIENCE: IMAGINE THE FUTURE, 2013, PARIS, FRANCE:99.",,,,F,Y,,,20150730,N,MD,KH,KH,Efavirenz,Abortion spontaneous;Exposure during pregnancy,113235481,OT,,,,,,,,,113235481,2,HIV infection
11323551,113235511,1,I,,20141124,20150730,20150730,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2014GSK028624,VIIV,"JANARDHANAN M, AMBERKAR MB, VIDYSAGAR S, KUMARI M AND HOLLA SN. HYPERSENSITIVITY REACTION ASSOCIATED WITH ABACAVIR THERAPY IN AN INDIAN  HIV PATIENT- A CASE REPORT. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. 2014;8 (9):1-2",44,YR,,M,Y,,,20150730,N,MD,IN,IN,EFAVIRENZ + LAMIVUDINE + TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain;Blood test abnormal;Decreased appetite;Fatigue;Headache;Hepatic function abnormal;Hypersensitivity;Pancytopenia;Pruritus;Rash;Skin lesion;Vomiting,113235511,OT,,,,,,,,,113235511,1,HIV infection
11323674,113236741,1,I,20150315,,20150729,20150729,DIR,,,,,35,YR,,M,N,,,20150325,N,PH,US,,EFAVIRENZ,Diarrhoea;Nausea;Weight decreased,,,113236741,HP,113236741,1,20150315,,,,113236741,1,Infection
11325265,113252651,1,I,20150216,20150721,20150730,20150730,EXP,,MW-ABBVIE-15P-100-1431097-00,ABBVIE,,34,YR,,F,Y,,,20150730,N,MD,COUNTRY NOT SPECIFIED,MW,SUSTIVA,Foetal death,113252651,OT,,,113252651,1,20141119,20150216,,,113252651,1,HIV infection
11325419,113254191,1,I,20150607,20150723,20150730,20150730,EXP,,BW-GILEAD-2015-0165113,GILEAD,,36,YR,A,F,Y,,,20150730,N,OT,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,113254191,OT,,,113254191,1,20140219,,,,113254191,1,HIV infection
11327055,113270551,1,I,20140807,20140815,20150731,20150731,EXP,,UG-VIIV HEALTHCARE LIMITED-B1024921A,VIIV,,24,YR,,F,Y,,,20150731,N,MD,UG,UG,EFAVIRENZ,Anaemia,113270551,LT,,,113270551,1,20140519,20140812,,,113270551,1,HIV infection
11327056,113270561,1,I,20140422,20140508,20150731,20150731,EXP,,UG-VIIV HEALTHCARE LIMITED-B0992543A,VIIV,,36,YR,,M,Y,,,20150731,N,MD,UG,UG,Efavirenz,Anaemia,113270561,LT,,,113270561,1,20140310,20140505,,,113270561,1,HIV infection
11327585,113275851,1,I,,20150722,20150731,20150731,EXP,,PHHY2015LS092159,SANDOZ,"SATTI H, MCLAUGHLIN MM, SEUNG KJ. DRUG-RESISTANT TUBERCULOSIS TREATMENT COMPLICATED BY ANTIRETROVIRAL RESISTANCE IN HIV COINFECTED PATIENTS: A REPORT OF SIX CASES IN LESOTHO. AM-J-TROP-MED-HYG. 2013;89(1):174-7",59,YR,,M,Y,,,20150731,N,OT,LS,LS,EFAVIRENZ,Death;Drug resistance,113275851,OT,,,,,,,,,113275851,1,HIV infection
11328253,113282531,1,I,,20150722,20150731,20150731,EXP,,PHHY2015LS092163,SANDOZ,"SATTI H, MCLAUGHLIN MM, SEUNG KJ. DRUG-RESISTANT TUBERCULOSIS TREATMENT COMPLICATED BY ANTIRETROVIRAL RESISTANCE IN HIV COINFECTED PATIENTS: A REPORT OF SIX CASES IN LESOTHO. AM-J-TROP-MED-HYG. 2013;89(1):174-7",45,YR,,M,Y,,,20150731,N,OT,LS,LS,EFAVIRENZ,Death;Drug resistance,113282531,DE,,,,,,,,,113282531,1,HIV infection
11329320,113293201,1,I,,20150720,20150803,20150803,EXP,,ZA-CIPLA LTD.-2015ZA06049,CIPLA,"ANNE DERACHE, CAROLE L. WALLIS, SARAN VARDHANABHUTI, JOHN BARTLETT, NAGALINGESWARAN KUMARASAMY, DAVID KATZENSTEIN. PHENOTYPE, GENOTYPE AND DRUG RESISTANCE IN SUBTYPE C HIV-1 INFECTION. 2015;1 TO 26",,,,,Y,,,20150803,N,OT,ZA,ZA,Efavirenz,Drug resistance;Gene mutation;Treatment failure,113293201,OT,,,,,,,,,113293201,1,HIV infection
11329321,113293211,1,I,,20150720,20150803,20150803,EXP,,ZA-CIPLA LTD.-2015ZA06051,CIPLA,"ANNE DERACHE, CAROLE L. WALLIS, SARAN VARDHANABHUTI, JOHN BARTLETT, NAGALINGESWARAN KUMARASAMY, DAVID KATZENSTEIN. PHENOTYPE, GENOTYPE AND DRUG RESISTANCE IN SUBTYPE C HIV-1 INFECTION. 2015;1 TO 26",,,,,Y,,,20150803,N,OT,ZA,ZA,Efavirenz,Drug resistance;Gene mutation;Treatment failure,113293211,OT,,,,,,,,,113293211,1,HIV infection
11329322,113293221,1,I,,20150720,20150803,20150803,EXP,,ZA-CIPLA LTD.-2015ZA06053,CIPLA,"ANNE DERACHE, CAROLE L. WALLIS, SARAN VARDHANABHUTI, JOHN BARTLETT, NAGALINGESWARAN KUMARASAMY, DAVID KATZENSTEIN. PHENOTYPE, GENOTYPE AND DRUG RESISTANCE IN SUBTYPE C HIV-1 INFECTION. 2015;1 TO 26",,,,,Y,,,20150803,N,OT,ZA,ZA,Efavirenz,Treatment failure,113293221,OT,,,,,,,,,113293221,1,HIV infection
11329393,113293931,1,I,,20150721,20150803,20150803,EXP,,FR-CIPLA LTD.-2015FR06080,CIPLA,"MOLINA J, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, SUPPARATPINYO K, WALMSLEY S.ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238-246",,,,,Y,,,20150803,N,MD,FR,FR,Efavirenz,Renal impairment,113293931,OT,,,,,,,,,113293931,1,HIV infection
11329401,113294011,1,I,,20150721,20150803,20150803,EXP,,FR-CIPLA LTD.-2015FR06081,CIPLA,"MOLINA J, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, SUPPARATPINYO K, WALMSLEY S.ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238-246",,,,,Y,,,20150803,N,OT,FR,FR,Efavirenz,Drug resistance;Gene mutation;Treatment failure,113294011,OT,,,,,,,,,113294011,1,HIV infection
11329403,113294031,1,I,,20150721,20150803,20150803,EXP,,FR-CIPLA LTD.-2015FR06083,CIPLA,"MOLINA J, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, SUPPARATPINYO K, WALMSLEY S.ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238-246",,,,,Y,,,20150803,N,OT,FR,FR,Efavirenz,Drug resistance;Gene mutation;Treatment failure,113294031,OT,,,,,,,,,113294031,1,HIV infection
11329667,113296671,1,I,,20150721,20150803,20150803,EXP,,US-CIPLA LTD.-2015US06095,CIPLA,"KRYST J, KAWALEC P, PILC A.. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL- NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015;10:1-23",,,,,Y,,,20150803,N,OT,PL,US,Efavirenz,Cerebrovascular accident,113296671,DE,,,,,,,,,113296671,1,HIV infection
11329672,113296721,1,I,,20150721,20150803,20150803,EXP,,US-CIPLA LTD.-2015US06094,CIPLA,"KRYST J, KAWALEC P, PILC A.. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL- NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015;10:1-23",,,,,Y,,,20150803,N,OT,PL,US,Efavirenz,Drug resistance;Gene mutation;Treatment failure,113296721,OT,,,,,,,,,113296721,1,HIV infection
11329675,113296751,1,I,,20150721,20150803,20150803,EXP,,US-CIPLA LTD.-2015US06075,CIPLA,"KRYST J, KAWALEC P, PILC A.. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL- NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015;10:1-23",,,,,Y,,,20150803,N,OT,PL,US,Efavirenz,Cerebral toxoplasmosis;Dysentery,113296751,DE,,,,,,,,,113296751,1,HIV infection
11329677,113296771,1,I,,20150721,20150803,20150803,EXP,,US-CIPLA LTD.-2015US06077,CIPLA,"KRYST J, KAWALEC P, PILC A.. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL- NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015;10:1-23",,,,,Y,,,20150803,N,OT,PL,US,Efavirenz,Respiratory failure,113296771,DE,,,,,,,,,113296771,1,HIV infection
11331364,113313641,1,I,,20150727,20150803,20150803,EXP,,US-GILEAD-2015-0165308,GILEAD,,63,YR,A,M,Y,,,20150803,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intervertebral disc protrusion;Retinal detachment;Stress;Visual acuity reduced,113313641,OT,,,,,,,,,113313641,1,HIV infection
11339701,113397011,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06192,CIPLA,"SUSANNA NAGGIE, CURTIS COOPER, MICHAEL SAAG, KIMBERLY WORKOWSKI, PETER RUANE, WILLIAM J. TOWNER ET AL. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1-9",,,,,Y,,,20150805,N,MD,US,US,Efavirenz,Ileus,113397011,OT,,,,,,,,,113397011,1,Hepatitis C virus test positive
11339704,113397041,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06187,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W J, MARKS K,ET.AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. TH E NEW ENGLAND JOURNAL O F MEDICINE. 2015;1-9",,,,,Y,,,20150805,N,OT,US,US,Efavirenz,Hepatocellular carcinoma,113397041,OT,,,,,,,,,113397041,1,HIV infection
11339721,113397211,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06188,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W J, MARKS K,ET.AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1-9",,,,,Y,,,20150805,N,OT,US,US,Efavirenz,Portal vein thrombosis,113397211,OT,,,,,,,,,113397211,1,HIV infection
11339724,113397241,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06193,CIPLA,"SUSANNA NAGGIE, CURTIS COOPER, MICHAEL SAAG, KIMBERLY WORKOWSKI, PETER RUANE, WILLIAM J. TOWNER ET AL. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1-9",,,,,Y,,,20150805,N,MD,US,US,Efavirenz,Peritonitis bacterial,113397241,OT,,,,,,,,,113397241,1,Hepatitis C
11339816,113398161,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06194,CIPLA,"SUSANNA NAGGIE, CURTIS COOPER, MICHAEL SAAG, KIMBERLY WORKOWSKI, PETER RUANE, WILLIAM J. TOWNER ET AL. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1-9",,,,,Y,,,20150805,N,MD,US,US,Efavirenz,Substance abuse,113398161,OT,,,,,,,,,113398161,1,Hepatitis C
11339828,113398281,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06201,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W J, MARKS K,ET.AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. TH E NEW ENGLAND JOURNAL O F MEDICINE. 2015;1 TO 9",,,,,Y,,,20150805,N,OT,US,US,Efavirenz,Hepatocellular carcinoma,113398281,OT,,,,,,,,,113398281,1,Hepatitis C
11339857,113398571,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06202,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W J, MARKS K,ET.AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL O F MEDICINE. 2015;1 TO 9",,,,,Y,,,20150805,N,OT,US,US,Efavirenz,Portal vein thrombosis,113398571,OT,,,,,,,,,113398571,1,Hepatitis C
11339889,113398891,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06205,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W J, MARKS K,ET.AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL O F MEDICINE. 2015;1 TO 9",,,,,Y,,,20150805,N,OT,US,US,Efavirenz,Cough,113398891,OT,,,,,,,,,113398891,1,Hepatitis C
11339893,113398931,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06209,CIPLA,SUSANNA.?NAGGIE@?DUKE.?EDU.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1-9,,,,,Y,,,20150805,N,OT,US,US,Efavirenz,Death;Endocarditis staphylococcal;Sepsis,113398931,DE,,,,,,,,,113398931,1,HIV infection
11339894,113398941,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06206,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W J, MARKS K,ET.AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV11. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1-9",,,,,Y,,,20150805,N,OT,US,US,Efavirenz,Death,113398941,DE,,,,,,,,,113398941,1,HIV infection
11339895,113398951,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06208,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W J, MARKS K,ET.AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV 1. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1-9",,,,,Y,,,20150805,N,OT,US,US,Efavirenz,Disease recurrence;Drug resistance,113398951,OT,,,,,,,,,113398951,1,HIV infection
11339944,113399441,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06212,CIPLA,LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV11. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1 TO 9,,,,,Y,,,20150805,N,OT,US,US,Efavirenz,Blood creatinine increased,113399441,OT,,,,,,,,,113399441,1,HIV infection
11339946,113399461,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06211,CIPLA,"SUSANNA NAGGIE, CURTIS COOPER,  MICHAEL SAAG, KIMBERLY WORKOWSKI,  PETER RUANE, WILLIAM J. TOWNER, ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV11. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1 TO 9",,,,,Y,,,20150805,N,OT,US,US,Efavirenz,Blood creatinine increased,113399461,OT,,,,,,,,,113399461,1,HIV infection
11339947,113399471,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015US06210,CIPLA,"NAGGIE S, COOPER C, SAAG M, WORKOWSKI K, RUANE P, TOWNER W J, MARKS K,ET.AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV11. THE NEW ENGLAND JOURNAL OF MEDICINE. 2015;1 TO 9",,,,,Y,,,20150805,N,OT,US,US,Efavirenz,Hypophosphataemia,113399471,OT,,,,,,,,,113399471,1,HIV infection
11340240,113402401,1,I,,20150724,20150805,20150805,EXP,,US-CIPLA LTD.-2015IN06204,CIPLA,"SUSANNA NAGGIE, CURTIS COOPER,  MICHAEL SAAG, KIMBERLY WORKOWSKI,  PETER RUANE, WILLIAM J. TOWNER, ET AL.. LEDIPASVIR AND SOFOSBUVIR FOR HCV IN PATIENTS COINFECTED WITH HIV-1. THE NEW ENGLAND JOURNAL O F MEDICINE. 2015;1 TO 9",,,,,Y,,,20150805,N,OT,US,US,Efavirenz,Azotaemia,113402401,OT,,,,,,,,,113402401,1,Hepatitis C
11342548,113425481,1,I,,20150728,20150805,20150805,EXP,,ET-GILEAD-2015-0165920,GILEAD,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150805,N,OT,ET,ET,EFAVIRENZ,Diabetes mellitus,113425481,OT,,,,,,,,,113425481,1,HIV infection
11342579,113425791,1,I,201504,20150729,20150805,20150805,EXP,,US-BMSGILMSD-2015-0165930,GILEAD,,43,YR,A,M,Y,,,20150805,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Brain injury;Road traffic accident,113425791,DS,,,,,,,,,113425791,1,HIV infection
11342666,113426661,1,I,,20150728,20150805,20150805,EXP,,ET-GILEAD-2015-0165921,GILEAD,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150805,N,OT,ET,ET,EFAVIRENZ,Diabetes mellitus,113426661,OT,,,,,,,,,113426661,1,HIV infection
11342835,113428351,1,I,,20150728,20150805,20150805,EXP,,ET-GILEAD-2015-0165923,GILEAD,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150805,N,OT,ET,ET,EFAVIRENZ,Diabetes mellitus,113428351,OT,,,,,,,,,113428351,1,HIV infection
11342836,113428361,1,I,,20150728,20150805,20150805,EXP,,ET-GILEAD-2015-0165922,GILEAD,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150805,N,OT,ET,ET,EFAVIRENZ,Diabetes mellitus,113428361,OT,,,,,,,,,113428361,1,HIV infection
11342838,113428381,1,I,,20150728,20150805,20150805,EXP,,ET-GILEAD-2015-0165924,GILEAD,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150805,N,OT,ET,ET,EFAVIRENZ,Diabetes mellitus,113428381,OT,,,,,,,,,113428381,1,HIV infection
11342839,113428391,1,I,,20150728,20150805,20150805,EXP,,ET-GILEAD-2015-0165925,GILEAD,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150805,N,OT,ET,ET,EFAVIRENZ,Diabetes mellitus,113428391,OT,,,,,,,,,113428391,1,HIV infection
11348844,113488441,1,I,20141105,20150723,20150806,20150806,EXP,,HT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-051188,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20150806,N,OT,HT,HT,EFAVIRENZ;Efavirenz,Abortion spontaneous;Maternal exposure during pregnancy,113488441,OT,,,113488441,1,20140918,20140922,,,113488441,1,HIV infection
11358689,113586892,2,F,20110205,20110309,20150803,20150831,PER,,US-ELI_LILLY_AND_COMPANY-US201102006384,ELI LILLY AND CO,,31,YR,,M,Y,70.3,KG,20150815,N,CN,US,US,SUSTIVA,Abdominal pain;Anxiety;Chest pain;Constipation;Depression;Disturbance in attention;Drug withdrawal syndrome;Dyskinesia;Erectile dysfunction;Fatigue;Generalised anxiety disorder;Hyperhidrosis;Hyperventilation;Hypoaesthesia;Impaired self-care;Insomnia;Irritability;Memory impairment;Mood swings;Muscle tightness;Nausea;Nervousness;Pain;Restlessness;Sexual dysfunction;Tremor;Vision blurred;Weight decreased;Weight increased,,,,,113586892,1,20110131,20110205,,,113586892,1,Fibromyalgia
11358774,113587741,1,I,20150403,,20150806,20150806,DIR,,,,,,,,M,N,66.8,KG,20150805,N,CN,US,,EFAVIRENZ,Abdominal pain;Constipation,113587741,HO,,,113587741,1,20150331,20150622,,,113587741,1,Hepatitis C
11359997,113599971,1,I,,20150729,20150810,20150810,EXP,,IN-MERCK-1508IND001989,MERCK,,56,YR,,M,Y,,,20150810,N,OT,IN,IN,EFAVIRENZ,Acquired immunodeficiency syndrome;Immune reconstitution inflammatory syndrome associated tuberculosis,113599971,OT,,,,,,,,,113599971,1,Pseudomonas infection
11362999,113629991,1,I,20150714,,20150807,20150807,DIR,,,,,34,YR,,M,N,63.0,KG,20150715,Y,OT,US,,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Neutropenic sepsis;Toxicity to various agents,113629991,LT,113629991,HP,113629991,1,20150305,20150713,,,113629991,1,HIV infection
11363064,113630641,1,I,,20150730,20150810,20150810,PER,,US-GILEAD-2015-0166134,GILEAD,,48,YR,A,F,Y,64,KG,20150810,N,MD,US,US,EFAVIRENZ,Drug ineffective;Drug resistance,113630641,OT,,,113630641,1,20130513,,,,113630641,1,HIV infection
11363510,113635101,1,I,,,20150810,20150810,DIR,,,,,53,YR,,M,N,,,,N,PH,US,,SUSTIVA,Pancreatitis,113635101,OT,113635101,HP,113635101,1,20150309,20150801,,,113635101,1,Lipodystrophy acquired
11363742,113637421,1,I,,20150803,20150811,20150811,EXP,,BR-ROCHE-1619078,ROCHE,"NEGRA M, CARVALHO A, DE AQUINO M, PINTO J, DA SILVA M, ANDREATTA K, GRAHAM B, LIU Y-P AND QUIRK E LONG-TERM EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN HIV-1-INFECTED ADOLESCENTS FAILING ANTIRETROVIRAL THERAPY: THE FINAL RESULTS OF STUDY GS-US-104-0321. PEDIATRIC INFECTIOUS DISEASE JOURNAL 2015 APR 21;34 (4):398-405.",,,,,Y,,,20150811,N,MD,BR,BR,EFAVIRENZ,Abscess;Abscess limb;Anogenital warts;Gastroenteritis;Herpes zoster;Neurocryptococcosis;Overdose;Pneumocystis jirovecii pneumonia;Pneumonia;Psychotic disorder;Pyelonephritis;Respiratory tract infection;Seizure;Sinusitis;Suicide attempt;Urinary tract infection,113637421,OT,,,,,,,,,113637421,1,HIV infection
11364522,113645221,1,I,,20150728,20150811,20150811,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2015112478,VIIV,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645221,OT,,,,,,,,,113645221,1,HIV infection
11364523,113645231,1,I,,20150728,20150811,20150811,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2015112467,VIIV,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645231,OT,,,,,,,,,113645231,1,HIV infection
11364526,113645261,1,I,,20150728,20150811,20150811,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2015112480,VIIV,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645261,OT,,,,,,,,,113645261,1,HIV infection
11364528,113645281,1,I,,20150728,20150811,20150811,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2015112474,VIIV,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150811,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645281,OT,,,,,,,,,113645281,1,HIV infection
11364530,113645301,1,I,,20150728,20150811,20150811,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2015112481,VIIV,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645301,OT,,,,,,,,,113645301,1,HIV infection
11364531,113645311,1,I,,20150728,20150811,20150811,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2015112479,VIIV,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645311,OT,,,,,,,,,113645311,1,HIV infection
11364575,113645751,1,I,,20150728,20150811,20150811,EXP,,ET-GLAXOSMITHKLINE-ET2015112478,GLAXOSMITHKLINE,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645751,OT,,,,,,,,,113645751,1,HIV infection
11364578,113645781,1,I,,20150728,20150811,20150811,EXP,,ET-GLAXOSMITHKLINE-ET2015112467,GLAXOSMITHKLINE,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645781,OT,,,,,,,,,113645781,1,HIV infection
11364583,113645831,1,I,,20150728,20150811,20150811,EXP,,ET-GLAXOSMITHKLINE-ET2015112480,GLAXOSMITHKLINE,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645831,OT,,,,,,,,,113645831,1,HIV infection
11364585,113645851,1,I,,20150728,20150811,20150811,EXP,,ET-GLAXOSMITHKLINE-ET2015112474,GLAXOSMITHKLINE,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206",,,A,,Y,,,20150811,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645851,OT,,,,,,,,,113645851,1,HIV infection
11364587,113645871,1,I,,20150728,20150811,20150811,EXP,,ET-GLAXOSMITHKLINE-ET2015112481,GLAXOSMITHKLINE,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645871,OT,,,,,,,,,113645871,1,HIV infection
11364596,113645961,1,I,,20150728,20150811,20150811,EXP,,ET-GLAXOSMITHKLINE-ET2015112479,GLAXOSMITHKLINE,"MOHAMMED, ABDUREHMAN ESHETE, ET AL. DIABETES MELLITUS AND RISK FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS AT JIMMA UNIVERSITY SPECIALIZED HOSPITAL, SOUTHWEST ETHIOPIA. DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY. 2015;8:197-206. 2015;8:197-206",,,A,,Y,,,20150811,N,OT,ET,ET,Efavirenz,Diabetes mellitus,113645961,OT,,,,,,,,,113645961,1,HIV infection
11365966,113659662,2,F,20150616,20150819,20150811,20150826,EXP,,FR-PFIZER INC-2015260804,PFIZER,,53,YR,,M,Y,,,20150826,N,OT,FR,FR,SUSTIVA,Depression;Panic attack;Suicidal ideation,113659662,OT,,,113659662,1,20150609,20150614,,,,,
11370858,113708582,2,F,20150616,20150824,20150812,20150828,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2015GSK113367,VIIV,,53,YR,,M,Y,,,20150828,N,OT,FR,FR,EFAVIRENZ;SUSTIVA,Depression;Panic attack;Suicidal ideation,113708582,OT,,,113708582,1,20150615,20150614,,,113708582,1,HIV infection
11371327,113713272,2,F,20150616,20150824,20150812,20150901,EXP,,FR-GILEAD-2015-0166665,GILEAD,,53,YR,A,M,Y,,,20150901,N,CN,FR,FR,SUSTIVA,Depression;Panic attack;Suicidal ideation,113713272,OT,,,113713272,1,20150615,2015,,,113713272,1,HIV infection
11381634,113816342,2,F,,20150814,20150814,20150827,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-051772,BRISTOL MYERS SQUIBB,,43,YR,,M,Y,111,KG,20150827,N,MD,BR,BR,EFAVIRENZ,Adverse event;Craniocerebral injury;Meningorrhagia,113816342,OT,,,113816342,1,20110727,,,,113816342,1,HIV infection
11384028,113840281,1,I,,20150807,20150815,20150815,EXP,,ES-CIPLA LTD.-2015ES06600,CIPLA,"RAMIREZ R., PEDROL E., LLIBRE J.M., TASIAS M., CURRAN A., GUARDIOLA J.M., ET AL.. OUTCOME OF NEUROPSYCHIATRIC SYMPTOMS RELATED TO AN ANTIRETROVIRAL DRUG FOLLOWING ITS SUBSTITUTION BY NEVIRAPINE: THE RELAX STUDY. HIV MEDICINE. 2015;1-7",,,,,Y,,,20150815,N,OT,ES,ES,Efavirenz,Nervous system disorder;Palpitations,113840281,OT,,,,,,,,,113840281,1,HIV infection
11389742,113897421,1,I,20120808,20150805,20150817,20150817,EXP,,TH-GILEAD-2015-0166983,GILEAD,,33,YR,A,F,Y,40.65,KG,20150817,N,MD,TH,TH,EFAVIRENZ,Hypophosphataemia,113897421,LT,,,113897421,1,20110912,20120111,,,113897421,1,HIV infection
11391056,113910561,1,I,,20150807,20150818,20150818,EXP,,ES-CIPLA LTD.-2015ES06602,CIPLA,"RAMIREZ R., PEDROL E., LLIBRE J.M., TASIAS M., CURRAN A., GUARDIOLA J.M., ET AL.. OUTCOME OF NEUROPSYCHIATRIC SYMPTOMS RELATED TO AN ANTIRETROVIRAL DRUG FOLLOWING ITS SUBSTITUTION BY NEVIRAPINE: THE RELAX STUDY. HIV MEDICINE. 2015;1-7",,,,,Y,,,20150818,N,OT,ES,ES,Efavirenz,Anal pruritus;Nervous system disorder,113910561,OT,,,,,,,,,113910561,1,HIV infection
11391063,113910631,1,I,,20150807,20150818,20150818,EXP,,ES-CIPLA LTD.-2015ES06601,CIPLA,"RAMIREZ R., PEDROL E., LLIBRE J.M., TASIAS M., CURRAN A., GUARDIOLA J.M., ET AL.. OUTCOME OF NEUROPSYCHIATRIC SYMPTOMS RELATED TO AN ANTIRETROVIRAL DRUG FOLLOWING ITS SUBSTITUTION BY NEVIRAPINE: THE RELAX STUDY. HIV MEDICINE. 2015;1-7",,,,,Y,,,20150818,N,MD,ES,ES,Efavirenz,Arthralgia;Nervous system disorder,113910631,OT,,,,,,,,,113910631,1,HIV infection
11392727,113927272,2,F,20150813,20150828,20150818,20150903,EXP,,US-GILEAD-2015-0167847,GILEAD,,59,YR,A,M,Y,70.3,KG,20150903,N,PH,US,US,EFAVIRENZ,Acute kidney injury;Creatinine renal clearance decreased,113927272,HO,,,113927272,1,201507,,,,113927272,1,Hepatitis C
11393459,113934591,1,I,,20150805,20150818,20150818,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-052669,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20150818,N,CN,GB,GB,EFAVIRENZ,Joint swelling,113934591,OT,,,113934591,2,20140826,,,,113934591,1,HIV infection
11394170,113941704,4,F,,20150826,20150819,20150909,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-053911,BRISTOL MYERS SQUIBB,,38,YR,,M,Y,,,20150909,N,MD,GB,GB,EFAVIRENZ,Joint swelling,113941704,OT,,,113941704,2,20140826,,,,113941704,1,HIV infection
11398182,113981822,2,F,,20150826,20150820,20150908,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-053005,BRISTOL MYERS SQUIBB,,38,YR,,M,Y,,,20150908,N,MD,GB,GB,SUSTIVA,Joint swelling,113981822,OT,,,113981822,2,20140826,,,,113981822,1,HIV infection
11399626,113996261,1,I,,20150806,20150820,20150820,EXP,,IN-MYLANLABS-2015M1027805,MYLAN,LINGESWARAN A. ANTIRETROVIRAL TREATMENT INDUCED CATATONIA IN 16-YEAR-OLD BOY. J-PEDIATR-NEUROSCI 2014; 9(3):283-285.,,,,,Y,,,20150820,N,MD,IN,IN,EFAVIRENZ,Catatonia,113996261,HO,,,,,,,,,113996261,1,HIV infection
11400950,114009501,1,I,20150702,20150602,20150820,20150820,EXP,,US-BMSGILMSD-2015-0162045,GILEAD,,45,YR,A,M,Y,53.61,KG,20150820,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Drug ineffective;Drug resistance;Treatment noncompliance,114009501,OT,,,114009501,1,20130418,20150702,,,114009501,1,HIV infection
11402228,114022281,1,I,,20131231,20150821,20150821,PER,,US-ROCHE-1328585,ROCHE,,,,,M,Y,,,20150821,N,CN,US,US,Efavirenz,Depression;Fatigue;Malaise,,,,,114022281,1,20131025,,,,114022281,1,Chronic hepatitis C
11403790,114037901,1,I,,20150806,20150821,20150821,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-055093,BRISTOL MYERS SQUIBB,LINGESWARAN A. ANTIRETROVIRAL TREATMENT INDUCED CATATONIA IN 16-YEAR-OLD BOY. JOURNAL PEDIATRIC NEUROSCIENCES. 2014;9(3):283-5,16,YR,,M,Y,,,20150821,N,MD,IN,IN,EFAVIRENZ,Catatonia,114037901,HO,,,,,,,,,114037901,1,HIV infection
11406000,114060002,2,F,,20150813,20150821,20150826,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-055386,BRISTOL MYERS SQUIBB,,,,,,Y,,,20150826,N,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Ventricular hypoplasia,114060002,OT,,,,,,,,,114060002,1,Product used for unknown indication
11407070,114070702,2,F,20150709,20150827,20150821,20150904,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-054443,BRISTOL MYERS SQUIBB,,63,YR,,F,Y,44,KG,20150904,N,OT,MW,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Neutropenia;Pneumonia,114070702,OT,,,114070702,1,20150603,20150708,,,114070702,1,HIV infection
11407604,114076041,1,I,,20150817,20150821,20150821,EXP,,US-GILEAD-2015-0168394,GILEAD,,24,YR,A,M,Y,,,20150821,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bipolar disorder,114076041,OT,,,,,,,,,114076041,1,Product used for unknown indication
11407819,114078192,2,F,20080422,20150813,20150821,20150826,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-055387,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20150826,N,MD,FR,FR,SUSTIVA,Abortion induced;Maternal exposure during pregnancy;Pregnancy on contraceptive,114078192,OT,,,114078192,1,200508,,,,114078192,1,Product used for unknown indication
11409750,114097501,1,I,201506,20150817,20150824,20150824,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2015GSK118107,VIIV,,66,YR,,M,Y,,,20150824,N,OT,FR,FR,SUSTIVA,Arthralgia,114097501,OT,,,114097501,1,201506,201506,,,114097501,1,Product used for unknown indication
11413937,114139371,1,I,20150411,20150820,20150824,20150824,EXP,,TH-GLAXOSMITHKLINE-TH2015GSK121047,GLAXOSMITHKLINE,,30,YR,,F,Y,,,20150824,N,CN,US,TH,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy,114139371,OT,,,114139371,1,20140604,,,,114139371,1,HIV infection
11414725,114147252,2,F,,20150915,20150825,20150925,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-054201,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20150925,N,PH,US,US,EFAVIRENZ,Gastrostomy;Neck surgery;Tracheostomy,114147252,HO,,,,,,,,,114147252,1,HIV infection
11415550,114155501,1,I,,20150824,20150825,20150825,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2015GSK121403,VIIV,LINGESWARAN A.. ANTIRETROVIRAL TREATMENT INDUCED CATATONIA IN 16-YEAR-OLD BOY.. JOURNAL OF PEDIATRIC NEUROSCIENCES. 2014;9;3:283-285,16,YR,,M,Y,,,20150825,N,OT,IN,IN,Efavirenz,Agitation;Brain scan abnormal;Catatonia;Drug withdrawal syndrome;Echopraxia;Grimacing;Mutism;Poor quality sleep,114155501,HO,,,,,,,,,114155501,1,HIV infection
11415553,114155531,1,I,20150411,20150820,20150825,20150825,EXP,,TH-VIIV HEALTHCARE LIMITED-TH2015GSK121047,VIIV,,30,YR,,F,Y,,,20150825,N,CN,US,TH,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy,114155531,OT,,,114155531,1,20140604,,,,114155531,1,HIV infection
11417878,114178781,1,I,,20150818,20150825,20150825,EXP,,AO-GILEAD-2015-0168532,GILEAD,"MANUEL A, VICTORIO T, GOMES C, MARTINS T, NETO A. VASCULITIS: AN UNUSUAL MANIFESTATION IN AN HIV-INFECTED PATIENT. THE BRAZILIAN JOURNAL OF INFECTIOUS DISEASES. 2015;19(4):439-441",30,YR,A,F,Y,,,20150825,N,OT,AO,AO,EFAVIRENZ,Vasculitis,114178781,OT,,,,,,,,,114178781,1,HIV infection
11421164,114211643,3,F,20150810,20150814,20150826,20150918,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-055688,BRISTOL MYERS SQUIBB,,33,YR,,M,Y,66,KG,20150918,N,OT,MW,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Anaemia;Kaposi's sarcoma,114211643,DE,,,114211643,1,20150201,20150610,,,114211643,1,Kaposi's sarcoma
11427013,114270131,1,I,20150411,20150820,20150827,20150827,EXP,,TH-GILEAD-2015-0168983,GILEAD,,30,YR,A,F,Y,,,20150827,N,OT,TH,TH,EFAVIRENZ,Abortion spontaneous,114270131,OT,,,114270131,1,20140604,,,,114270131,1,HIV infection
11427734,114277341,1,I,,20150818,20150828,20150828,EXP,,GB-CIPLA LTD.-2015GB06837,CIPLA,"WONG D, WALMSLEY S, BAUMGARTEN A, BERENGUER J, FELIZARTA F, FLORENCE E, KHUONG-JOSSES M ET AL.. DOLUTEGRAVIR PLUS ABACAVIR/LAMIVUDINE FOR THE TREATMENT OF HIV-1 INFECTION IN ANTIRETROVIRAL THERAPY NAIVE PATIENTS: WEEK 96 AND WEEK 144 RESULTS FROM THE SINGLE RANDOMIZED CLINICAL TRIAL. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES",,,,,Y,,,20150828,N,OT,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Drug resistance;Virologic failure,114277341,OT,,,,,,,,,114277341,1,HIV infection
11427770,114277701,1,I,,20150818,20150828,20150828,EXP,,GB-CIPLA LTD.-2015GB06842,CIPLA,"WONG D, WALMSLEY S, BAUMGARTEN A, BERENGUER J, FELIZARTA F, FLORENCE E, KHUONG-JOSSES M ET AL.. DOLUTEGRAVIR PLUS ABACAVIR/LAMIVUDINE FOR THE TREATMENT OF HIV-1 INFECTION IN ANTIRETROVIRAL THERAPY-NAIVE PATIENTS: WEEK 96 AND WEEK 144 RESULTS FROM THE SINGLE RANDOMIZED CLINICAL TRIAL. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES",,,,,Y,,,20150828,N,OT,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Acute hepatitis C,114277701,OT,,,,,,,,,114277701,1,HIV infection
11432913,114329131,1,I,,20150824,20150828,20150828,EXP,,US-BMSGILMSD-2015-0169396,GILEAD,,50,YR,A,M,Y,,,20150828,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Prostate cancer,114329131,HO,,,,,,,,,114329131,1,HIV infection
11438119,114381191,1,I,,20150821,20150901,20150901,EXP,,PHHY2015GB103493,SANDOZ,"PAYNE BA, GARDNER K, BLAKELY EL, MADDISON P, HORVATH R, TAYLOR RW, ET AL.. CLINICAL AND PATHOLOGICAL FEATURES OF MITOCHONDRIAL DNA DELETION DISEASE FOLLOWING ANTIRETROVIRAL TREATMENT.. JAMA-NEUROL. 2015;72(5):603-5",63,YR,,M,Y,,,20150901,N,OT,GB,GB,EFAVIRENZ,Mitochondrial myopathy;Myalgia,114381191,OT,,,,,,,,,114381191,1,HIV infection
11438122,114381221,1,I,,20150821,20150901,20150901,EXP,,PHHY2015GB102794,SANDOZ,"PAYNE BA, GARDNER K, BLAKELY EL, MADDISON P, HORVATH R, TAYLOR RW, ET AL.. CLINICAL AND PATHOLOGICAL FEATURES OF MITOCHONDRIAL DNA DELETION DISEASE FOLLOWING ANTIRETROVIRAL TREATMENT.. JAMA-NEUROL. 2015;72(5):603-5",55,YR,,M,Y,,,20150901,N,OT,GB,GB,EFAVIRENZ,Mitochondrial myopathy,114381221,OT,,,,,,,,,114381221,1,HIV infection
11441114,114411141,1,I,20150814,,20150831,20150831,DIR,,,,,54,YR,,M,N,145,LBS,20150830,N,,US,,SUSTIVA,Arthralgia;Drug dependence;Drug withdrawal syndrome;Joint stiffness,,,,,,,,,,,114411141,1,Type 2 diabetes mellitus
11441892,114418921,1,I,20140717,20150824,20150901,20150901,EXP,ES-AGEMED-609137244,ES-VIIV HEALTHCARE LIMITED-ES2015120897,VIIV,,39,YR,,F,Y,,,20150901,N,MD,ES,ES,Efavirenz,Pancreatitis acute;Portal vein thrombosis;Splenic thrombosis,114418921,HO,,,114418921,1,2009,20140717,,,114418921,1,HIV infection
11442100,114421001,1,I,20140717,20150824,20150901,20150901,EXP,ES-AGEMED-609137244,ES-GLAXOSMITHKLINE-ES2015120897,GLAXOSMITHKLINE,,39,YR,,F,Y,,,20150901,N,MD,ES,ES,Efavirenz,Pancreatitis acute;Portal vein thrombosis;Splenic thrombosis,114421001,OT,,,114421001,1,2009,20140717,,,114421001,1,HIV infection
11442450,114424501,1,I,20150330,20150407,20150901,20150901,EXP,,MW-GILEAD-2015-0147770,GILEAD,,36,YR,A,M,Y,,,20150901,N,MD,MW,MW,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma;Pneumonia,114424501,DE,,,114424501,1,20150316,,,,114424501,1,HIV infection
11443614,114436141,1,I,20080807,20150828,20150901,20150901,EXP,,ZW-ABBVIE-15P-190-1454559-00,ABBVIE,,36,YR,,F,Y,,,20150901,N,OT,COUNTRY NOT SPECIFIED,ZW,SUSTIVA,Abortion spontaneous;Exposure during pregnancy,114436141,OT,,,114436141,1,20071101,20080612,,,114436141,1,Product used for unknown indication
11449230,114492301,1,I,,20150828,20150902,20150902,EXP,,UG-ABBVIE-15P-165-1454522-00,ABBVIE,,35,YR,,F,Y,,,20150902,N,OT,COUNTRY NOT SPECIFIED,UG,SUSTIVA,Abortion induced;Exposure during pregnancy,114492301,OT,,,114492301,1,20070503,20080721,,,114492301,1,Antiretroviral therapy
11449260,114492601,1,I,20081101,20150828,20150902,20150902,EXP,,UG-ABBVIE-15P-165-1454544-00,ABBVIE,,35,YR,,F,Y,,,20150902,N,OT,COUNTRY NOT SPECIFIED,UG,SUSTIVA,Exposure during pregnancy;Stillbirth,114492601,OT,,,114492601,1,20070828,20080904,,,114492601,1,HIV infection
11449274,114492741,1,I,20090315,20150828,20150902,20150902,EXP,,UG-ABBVIE-15P-165-1454564-00,ABBVIE,,27,YR,,F,Y,,,20150902,N,OT,COUNTRY NOT SPECIFIED,UG,SUSTIVA,Abortion spontaneous;Exposure during pregnancy,114492741,OT,,,114492741,1,20090303,20090303,,,114492741,1,HIV infection
11451882,114518821,1,I,,20150821,20150903,20150903,EXP,,GB-MYLANLABS-2015M1029506,MYLAN,"PAYNE BA, GARDNER K, BLAKELY EL, MADDISON P, HORVATH R, TAYLOR RW, ET AL. CLINICAL AND PATHOLOGICAL FEATURES OF MITOCHONDRIAL DNA DELETION DISEASE FOLLOWING ANTIRETROVIRAL TREATMENT. JAMA-NEUROL 2015; 72(5):603-5.",,,,,Y,,,20150903,N,OT,GB,GB,EFAVIRENZ,Mitochondrial myopathy,114518821,OT,,,,,,,,,114518821,1,HIV infection
11451908,114519081,1,I,,20150821,20150903,20150903,EXP,,GB-MYLANLABS-2015M1029507,MYLAN,"PAYNE BA, GARDNER K, BLAKELY EL, MADDISON P, HORVATH R, TAYLOR RW, ET AL. CLINICAL AND PATHOLOGICAL FEATURES OF MITOCHONDRIAL DNA DELETION DISEASE FOLLOWING ANTIRETROVIRAL TREATMENT. JAMA-NEUROL 2015; 72(5):603-5.",,,,,Y,,,20150903,N,OT,GB,GB,EFAVIRENZ,Mitochondrial myopathy,114519081,OT,,,,,,,,,114519081,1,HIV infection
11457454,114574541,1,I,,20150903,20150904,20150904,EXP,,CA-ROCHE-1630215,ROCHE,,,,,M,Y,,,20150904,N,OT,CA,CA,SUSTIVA,Depression;Drug interaction,114574541,OT,,,,,,,,,114574541,1,Product used for unknown indication
11457592,114575921,1,I,,20150818,20150902,20150902,EXP,,2015HINLIT0706,HETERO,,16,YR,,M,N,,,20150831,N,MD,IN,,EFAVIRENZ (EFAVIRENZ),Catatonia,114575921,HO,114575921,LIT,,,,,,,114575921,1,HIV infection
11457705,114577051,1,I,20150411,20150824,20150904,20150904,EXP,,TH-AUROBINDO-AUR-APL-2015-07787,AUROBINDO,,30,YR,,F,Y,,,20150904,N,MD,TH,TH,EFAVIRENZ 600MG,Abortion spontaneous;Exposure during pregnancy,114577051,OT,,,114577051,1,20140604,,,,114577051,1,HIV infection
11460939,114609392,2,F,20150411,20150820,20150904,20150908,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-057252,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20150908,N,OT,TH,TH,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,114609392,OT,,,114609392,1,20140604,,,,114609392,1,HIV infection
11463098,114630982,2,F,,20150821,20150905,20150908,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-060207,BRISTOL MYERS SQUIBB,,63,YR,,M,Y,,,20150908,N,OT,GB,GB,EFAVIRENZ,Mitochondrial myopathy,114630982,OT,,,,,,,,,114630982,1,HIV infection
11463106,114631062,2,F,,20150821,20150905,20150908,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-059139,BRISTOL MYERS SQUIBB,,55,YR,,M,Y,,,20150908,N,OT,GB,GB,EFAVIRENZ,Mitochondrial myopathy,114631062,OT,,,,,,,,,114631062,1,HIV infection
11465428,114654281,1,I,,20150903,20150907,20150907,EXP,,CA-ROCHE-1630210,ROCHE,,84,YR,,M,Y,,,20150907,N,OT,CA,CA,SUSTIVA,Depression;Drug interaction,114654281,OT,,,,,,,,,114654281,1,Product used for unknown indication
11466628,114666281,1,I,,20150821,20150907,20150907,EXP,,GB-009507513-1509GBR003527,MERCK,,63,YR,,M,Y,,,20150907,N,CN,US,GB,EFAVIRENZ,Mitochondrial myopathy,114666281,OT,,,,,,,,,114666281,1,HIV infection
11481725,114817251,1,I,201504,20150903,20150909,20150909,EXP,,US-GILEAD-2015-0170920,GILEAD,,46,YR,A,F,Y,,,20150909,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus,114817251,OT,,,,,,,,,114817251,1,HIV infection
11489460,114894602,2,F,20150813,20150924,20150909,20150929,EXP,,US-ASTELLAS-2015US030981,ASTELLAS,,,,,M,Y,,,20150929,N,MD,US,US,SUSTIVA,Haematuria;Non-cardiac chest pain;Respiratory failure;Sepsis,114894602,OT,,,114894602,1,20150806,20150828,,,114894602,1,Non-small cell lung cancer
11493385,114933851,1,I,,20150829,20150911,20150911,EXP,,GB-LUPIN PHARMACEUTICALS INC.-2015-02744,LUPIN,"PAYNE B, GARDNER K, HORVATH R, CHINNERY P, BLAKELY E, TAYLOR R, MADDISON P. CLINICAL AND PATHOLOGICAL FEATURES OF MITOCHONDRIAL DNA DELETION DISEASE FOLLOWING ANTIRETROVIRAL TREATMENT. JAMA NEUROLOGY. 2015 MAY;72(5):603-605.",63,YR,,M,Y,,,20150911,N,,COUNTRY NOT SPECIFIED,GB,Efavirenz,Mitochondrial myopathy,114933851,OT,,,,,,,,,114933851,1,HIV infection
11500094,115000941,1,I,20140423,20150907,20150914,20150914,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2015GSK129083,VIIV,,40,YR,,,Y,,,20150914,N,MD,UG,UG,Efavirenz,Anaemia,115000941,LT,,,115000941,1,20140326,20140618,,,115000941,1,HIV infection
11515214,115152141,1,I,2007,20150909,20150916,20150916,EXP,ES-AGEMED-109233444,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-061619,BRISTOL MYERS SQUIBB,,48,YR,,M,Y,,,20150916,N,CN,ES,ES,EFAVIRENZ,Cellulitis;Cholesterosis;Haemothorax;Monarthritis;Neutropenia;Pneumonia;Polyarthritis;Type 2 diabetes mellitus,115152141,OT,,,115152141,1,2006,20140911,,,115152141,1,HIV infection
11515807,115158071,1,I,20150910,20150911,20150916,20150916,EXP,,US-BMSGILMSD-2015-0172189,GILEAD,,64,YR,,M,Y,,,20150916,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain;Fall;Neoplasm malignant;Peripheral swelling,115158071,OT,,,,,,,,,115158071,1,HIV infection
11518514,115185141,1,I,,20150908,20150917,20150917,EXP,,US-JNJFOC-20150905804,JANSSEN,"STEK A, BEST BM, WANG J, CAPPARELLI EV, BURCHETT SK, KREITCHMANN R, ET AL. PHARMACOKINETICS OF ONCE VERSUS TWICE DAILY DARUNAVIR IN PREGNANT HIV-INFECTED WOMEN. JAIDS JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 01-SEP-2015;70 (1):33-41.",,,,F,Y,,,20150917,N,OT,US,US,EFAVIRENZ,Exposure during pregnancy;Foetal growth restriction;Gestational diabetes;Hypercholesterolaemia;Liver function test abnormal;Premature labour,115185141,OT,,,,,,,,,115185141,1,HIV infection
11525401,115254011,1,I,,20150908,20150918,20150918,EXP,,US-JNJFOC-20150909154,JANSSEN,"STEK A, BEST BM, WANG J, CAPPARELLI EV, BURCHETT SK, KREITCHMANN R, ET AL. PHARMACOKINETICS OF ONCE VERSUS TWICE DAILY DARUNAVIR IN PREGNANT HIV-INFECTED WOMEN. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 01-SEP-2015;70 (1):33-41.",,,,,Y,,,20150918,N,MD,US,US,EFAVIRENZ,Atrial septal defect;Cardiac murmur;Foetal exposure during pregnancy,115254011,CA,,,,,,,,,115254011,1,HIV infection
11525693,115256931,1,I,2013,20150914,20150918,20150918,EXP,,US-GILEAD-2015-0172208,GILEAD,,38,YR,A,M,Y,,,20150918,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,115256931,OT,,,,,,,,,115256931,1,HIV infection
11525986,115259861,1,I,,20150911,20150918,20150918,EXP,,US-BMSGILMSD-2015-0172096,GILEAD,,40,YR,A,M,Y,,,20150918,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastrointestinal infection,115259861,HO,,,115259861,1,20100101,,,,115259861,1,HIV infection
11546172,115461721,1,I,,20150909,20150924,20150924,EXP,,IE-CIPLA LTD.-2015IE07429,CIPLA,"SHERIF O, KHOOB S, AND CAROLINE SOLAS. KEY DRUG-DRUG INTERACTIONS WITH DIRECT-ACTING ANTIVIRAL IN HIV-HCV COINFECTION. CURR OPIN HIV AIDS. 2015;10 (5):348-354",,,,,Y,,,20150924,N,OT,IE,IE,Efavirenz,Blood creatinine increased,115461721,OT,,,,,,,,,115461721,1,HIV infection
11546193,115461931,1,I,,20150909,20150924,20150924,EXP,,IE-CIPLA LTD.-2015IE07428,CIPLA,"SHERIF O, KHOOB S, AND CAROLINE SOLAS. KEY DRUG-DRUG INTERACTIONS WITH DIRECT-ACTING ANTIVIRAL IN HIV-HCV COINFECTION. CURR OPIN HIV AIDS. 2015;10 (5):348-354",,,,,Y,,,20150924,N,OT,IE,IE,Efavirenz,Blood creatinine increased,115461931,OT,,,,,,,,,115461931,1,HIV infection
11550264,115502641,1,I,20150622,20150917,20150924,20150924,EXP,,ZA-GILEAD-2015-0173671,GILEAD,,31,YR,A,F,Y,38,KG,20150924,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood alkaline phosphatase increased;Gamma-glutamyltransferase increased,115502641,HO,,,115502641,1,201505,,,,115502641,1,HIV infection
11554335,115543351,1,I,,20150917,20150925,20150925,EXP,,PHHY2015FR113792,SANDOZ,"FOURCADE C, MAUBOUSSIN J-M, LECHICHE C, LAVIGNE J-P, SOTTO A. THALIDOMIDE IN THE TREATMENT OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV PATIENTS WITH NEUROLOGICAL TUBERCULOSIS. AIDS-PATIENT-CARE-STD. 2014;28 (11):567-9",51,YR,,F,Y,,,20150925,N,OT,FR,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,115543351,HO,,,,,,,,,115543351,1,Tuberculosis
11564310,115643101,1,I,2012,20150921,20150928,20150928,EXP,,BR-ABBVIE-15P-020-1469315-00,ABBVIE,,,,,F,Y,46,KG,20150928,N,CN,BR,BR,EFAVIRENZ,Blindness;Dyspnoea;HIV infection;Malaise;Pain in extremity;Rash macular;Sensory disturbance;Skin discolouration;Visual acuity reduced;Weight decreased;Wound,115643101,DS,,,115643101,1,2007,2011,,,115643101,1,HIV infection
11567432,115674321,1,I,20150411,20150821,20150925,20150925,EXP,,2015HINCT 0709,HETERO,,30,YR,,F,N,,,20150902,N,OT,TH,,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,115674321,OT,115674321,FGN,115674321,1,20140604,,,,115674321,1,HIV infection
6535257,653525712,12,F,200707,20150715,20080125,20150730,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14053466,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20150730,N,CN,GB,GB,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,653525712,OT,,,653525712,1,20021001,20070816,,,653525712,1,HIV infection
6631522,66315225,5,F,20080125,20150730,20080502,20150811,EXP,,FR-GILEAD-2008-0016228,GILEAD,,26,YR,A,F,Y,,,20150811,N,OT,FR,FR,SUSTIVA,Abortion induced;Congenital anomaly;Ultrasound antenatal screen abnormal,66315225,CA,,,66315225,1,20060101,,,,66315225,1,HIV infection
7124197,71241973,3,F,,20120905,20090921,20150722,PER,,US-GILEAD-2009-0023795,GILEAD,,31,YR,A,F,Y,,,20150722,N,OT,US,US,EFAVIRENZ,Neutropenia,71241973,OT,,,71241973,1,200805,,,,71241973,1,HIV infection
7152253,71522538,8,F,,20150804,20091019,20150811,EXP,,CA-PFIZER INC-2009279889,PFIZER,"PFEFFER, G.. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY. 2009;73 (1):71-72",52,YR,,M,Y,,,20150811,N,OT,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,71522538,OT,,,,,,,,,71522538,1,HIV infection
7155921,71559216,6,F,,20150804,20091022,20150806,EXP,,CA-ROCHE-663583,ROCHE,"PFEFFER G, PFEFFER G, COTE H, MONTANER J, LI C, JITRATKOSOL M AND MEZEI M. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY 2009;73 (1):71-72.",52,YR,,M,Y,,,20150806,N,MD,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,71559216,OT,,,,,,,,,71559216,1,HIV infection
7381425,73814253,3,F,,20150715,20100507,20150724,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2010-BP-04936BP",BOEHRINGER INGELHEIM,,27,YR,,F,Y,,,20150724,N,MD,COUNTRY NOT SPECIFIED,GB,EFAVIRENZ,Abortion induced,73814253,OT,,,73814253,1,20070816,,,,73814253,1,Antiviral treatment
8383331,83833312,2,F,20101120,20150728,20120201,20150807,EXP,GB-MHRA-ADR 21453021,GB-GILEAD-2011-0044189,GILEAD,,37,YR,A,F,Y,,,20150807,N,MD,GB,GB,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Headache;Live birth;Maternal exposure during pregnancy,83833312,OT,,,83833312,1,20100301,20110901,,,83833312,1,HIV infection
8691284,86912847,7,F,20090824,20150817,20120730,20150831,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-16789448,BRISTOL MYERS SQUIBB,,41,YR,,M,Y,,,20150831,N,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Full blood count decreased;Hepatitis C,86912847,OT,,,86912847,1,20000901,20100711,,,86912847,1,HIV infection
8696154,86961546,6,F,20090824,20150817,20120801,20150831,EXP,,JP-009507513-1207JPN000172,MERCK,,41,YR,,M,Y,,,20150831,N,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Full blood count decreased;Hepatitis C,86961546,OT,,,86961546,1,20000901,20100711,,,86961546,1,HIV infection
8786525,87865253,3,F,20120808,20120918,20120914,20150917,EXP,,TH-GILEAD-2012-0060984,GLAXOSMITHKLINE,,33,YR,,F,Y,,,20150917,N,MD,TH,TH,EFAVIRENZ,Hypophosphataemia,87865253,LT,,,87865253,1,20120111,20120111,,,87865253,1,HIV infection
8817347,88173476,6,F,20120922,20121005,20121004,20150928,EXP,,TH-GILEAD-2012-0062224,VIIV,,27,YR,,M,Y,,,20150928,N,MD,TH,TH,Efavirenz,Electrolyte imbalance,88173476,HO,,,88173476,4,20100925,20120219,,,88173476,2,HIV infection
9291064,92910645,5,F,,20130516,20130515,20150731,EXP,,ZA-GILEAD-2013-0075045,VIIV,"LEHLOENYA R, SHEBE K, HLELA C, DLAMINI S, MANKAHLA A, LAPINER V, MEINTJES G, TODD G. AGGRESSIVE WORSENING OF SEZARY SYNDROME DURING EARLY ANTIRETROVIRAL THERAPY.. AIDS. DATE OF PUBLICATION: 27 MAR 2013. 2013;27 (6):1035-1036",55,YR,,F,Y,,,20150731,N,OT,ZA,ZA,Efavirenz,Mycosis fungoides,92910645,DE,,,92910645,1,201108,,,,,,
9398550,93985503,3,F,201111,20150803,20130712,20150814,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-19099720,BRISTOL MYERS SQUIBB,,46,YR,,M,Y,,,20150814,N,CN,US,JP,EFAVIRENZ,Angina pectoris;Movement disorder;Nightmare,93985503,OT,,,93985503,1,20010624,20130108,,,93985503,1,HIV infection
9468888,94688885,5,F,,20130822,20130821,20150731,EXP,,LS-GILEAD-2013-0081502,VIIV,"SATTI H., MCLAUGHLIN M.M., SEUNG K.J.. SHORT REPORT: DRUG-RESISTANT TUBECULOSIS TREATMENT COMPLICATED BY ANTIRETROVIRAL RESISTANCE IN HIV COINFECTED PATIENTS: A REPORT OF SIX CASES IN LESOTHO. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. 2013;89 (1):174-177",45,YR,,M,Y,,,20150731,N,MD,LS,LS,Efavirenz,Drug resistance;Viral mutation identified,94688885,OT,,,,,,,,,94688885,2,HIV infection
9694317,96943173,3,F,20070911,20071001,20131118,20150803,PER,,US-GILEAD-2007-0013385,GILEAD,,53,YR,,M,Y,,,20150803,N,CN,US,US,SUSTIVA,Hepatic enzyme increased,96943173,OT,,,96943173,1,20070809,20070912,,,96943173,1,Pulmonary arterial hypertension
9701423,97014233,3,F,20080513,20080610,20131121,20150803,PER,,US-GILEAD-2008-0016495,GILEAD,,41,YR,A,F,Y,,,20150803,N,MD,US,US,SUSTIVA,Dizziness;Headache;Nausea,,,,,97014233,1,20080512,,,,97014233,1,Pulmonary arterial hypertension
9723226,97232262,2,F,20080804,20080923,20131202,20150727,PER,,US-GILEAD-2008-0018231,GILEAD,,49,YR,A,M,Y,,,20150727,N,OT,US,US,SUSTIVA,Acute kidney injury,97232262,OT,,,97232262,1,200703,20080807,,,97232262,1,HIV infection
9723230,97232303,3,F,200802,20080411,20131202,20150727,PER,,US-GILEAD-2008-0015610,GILEAD,,48,YR,,F,Y,60.78,KG,20150727,N,MD,US,US,SUSTIVA,Oesophageal pain;Oesophageal ulcer,,,,,97232303,1,2007,,,,97232303,1,Acquired immunodeficiency syndrome
9746039,97460392,2,F,,20090722,20131211,20150722,PER,,ES-GILEAD-2009-0023268,GILEAD,,,,A,M,Y,,,20150722,N,PH,ES,ES,SUSTIVA,Hallucination;Pain;Pruritus generalised,,,,,,,,,,,97460392,1,Product used for unknown indication
9746050,97460502,2,F,20090728,20090731,20131211,20150722,PER,,GB-GILEAD-2009-0023437,GILEAD,,,,,M,Y,,,20150722,N,PH,GB,GB,SUSTIVA,Dizziness;Insomnia,,,,,97460502,1,20090727,,,,97460502,1,HIV infection
9746054,97460543,3,F,,20090724,20131211,20150722,PER,,DE-GILEAD-2009-0023267,GILEAD,,,,,F,Y,,,20150722,N,OT,DE,DE,SUSTIVA,Disturbance in attention,,,,,,,,,,,97460543,1,Product used for unknown indication
9746071,97460712,2,F,,20090903,20131211,20150722,PER,,GB-GILEAD-2009-0024099,GILEAD,,,,,M,Y,,,20150722,N,MD,GB,GB,SUSTIVA,Abnormal dreams;Dizziness,,,,,,,,,,,97460712,1,Product used for unknown indication
9746075,97460753,3,F,200805,20090903,20131211,20150722,PER,,FR-GILEAD-2009-0023718,GILEAD,,,,,M,Y,,,20150722,N,MD,FR,FR,SUSTIVA,Dermatitis allergic;Toxic skin eruption,,,,,97460753,1,20090729,20090128,,,97460753,1,HIV infection
9746076,97460762,2,F,20081121,20090916,20131211,20150722,PER,,GB-GILEAD-2009-0024395,GILEAD,,61,YR,,M,Y,78,KG,20150722,N,OT,GB,GB,EFAVIRENZ,Unevaluable event,,,,,97460762,1,20081120,20081130,,,97460762,1,HIV infection
9746085,97460852,2,F,,20090923,20131211,20150722,PER,,ES-GILEAD-2009-0024438,GILEAD,,,,A,M,Y,,,20150722,N,MD,ES,ES,EFAVIRENZ,Nervous system disorder,,,,,,,,,,,97460852,1,HIV infection
9746086,97460863,3,F,,20091021,20131211,20150722,PER,,PT-GILEAD-2009-0024517,GILEAD,,,,A,M,Y,,,20150722,N,MD,PT,PT,EFAVIRENZ,Sleep disorder,,,,,,,,,,,97460863,1,HIV infection
9746092,97460923,3,F,20090920,20091015,20131211,20150722,PER,,FR-GILEAD-2009-0024551,GILEAD,,41,YR,,F,Y,90,KG,20150722,N,MD,FR,FR,SUSTIVA,Hypersensitivity,,,,,97460923,1,20090913,20090928,,,97460923,1,HIV infection
9746104,97461043,3,F,,20091130,20131211,20150722,PER,,DE-GILEAD-2009-0024394,GILEAD,,,,A,F,Y,,,20150722,N,MD,DE,DE,SUSTIVA,Rash pruritic,,,,,,,,,,,97461043,1,HIV infection
9746116,97461162,2,F,,20091021,20131211,20150722,PER,,GB-GILEAD-2009-0024958,GILEAD,,14,YR,,M,Y,,,20150722,N,OT,GB,GB,EFAVIRENZ,Arthralgia;Dizziness;Nervous system disorder;Off label use,,,,,,,,,,,97461162,1,HIV infection
9746143,97461432,2,F,,20091203,20131211,20150722,PER,,FR-GILEAD-2009-0025864,GILEAD,,,,,F,Y,,,20150722,N,MD,FR,FR,SUSTIVA,Diarrhoea,,,,,,,,,,,,,
9746154,97461542,2,F,,20091209,20131211,20150722,PER,,GB-GILEAD-2009-0025975,GILEAD,,,,,M,Y,,,20150722,N,MD,GB,GB,EFAVIRENZ,Abnormal dreams;Nightmare,,,,,,,,,,,,,
9746155,97461552,2,F,,20091209,20131211,20150722,PER,,GB-GILEAD-2009-0025976,GILEAD,,,,,M,Y,,,20150722,N,MD,GB,GB,EFAVIRENZ,Abnormal dreams;Nightmare,,,,,,,,,,,,,
9746158,97461583,3,F,20091119,20091204,20131211,20150722,PER,,US-BMSGILMSD-2009-0025758,GILEAD,,43,YR,,F,Y,,,20150722,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aspartate aminotransferase increased,97461583,OT,,,97461583,1,20090731,20091031,,,97461583,1,HIV infection
9746169,97461693,3,F,,20100111,20131211,20150722,PER,,ES-GILEAD-2009-0024809,GILEAD,,,,,M,Y,68,KG,20150722,N,PH,ES,ES,EFAVIRENZ,Diarrhoea;Gastrointestinal disorder;Weight decreased,,,,,,,,,,,97461693,1,HIV infection
9746173,97461733,3,F,,20100303,20131211,20150722,PER,,FR-GILEAD-2009-0025695,GILEAD,,,,,M,Y,,,20150722,N,MD,FR,FR,SUSTIVA,Diabetes mellitus inadequate control,,,,,,,,,,,97461733,2,Product used for unknown indication
9746174,97461743,3,F,,20100219,20131211,20150722,PER,,GB-GILEAD-2009-0025970,GILEAD,,65,YR,,M,Y,,,20150722,N,MD,GB,GB,EFAVIRENZ,Abnormal dreams;Nightmare;Paraesthesia,,,,,97461743,1,20090325,,,,,,
9746177,97461772,2,F,,20091216,20131211,20150722,PER,,FR-GILEAD-2009-0026188,GILEAD,,,,,F,Y,,,20150722,N,MD,FR,FR,SUSTIVA,Mental disorder,,,,,,,,,,,97461772,2,Product used for unknown indication
9746182,97461822,2,F,200911,20091215,20131211,20150722,PER,,FR-GILEAD-2009-0026072,GILEAD,,44,YR,,M,Y,,,20150722,N,MD,FR,FR,SUSTIVA,Gynaecomastia,,,,,97461822,1,20090528,20090527,,,,,
9753877,97538773,3,F,201001,20100319,20131213,20150805,PER,,US-GILEAD-2010-0027759,GILEAD,,55,YR,,M,Y,93.44,KG,20150805,N,PH,US,US,SUSTIVA,Aspartate aminotransferase increased,,,,,97538773,1,20081112,201001,,,97538773,1,Pulmonary arterial hypertension
9767542,97675423,3,F,,20090902,20131217,20150731,PER,,US-GILEAD-2009-0023022,GILEAD,,40,YR,A,M,Y,,,20150731,N,MD,US,US,SUSTIVA,Blood creatinine increased,97675423,HO,,,,,,,,,97675423,1,HIV infection
9767580,97675803,3,F,20090629,20091104,20131217,20150731,PER,,US-GILEAD-2009-0022878,GILEAD,,18,YR,,M,Y,,,20150731,N,MD,US,US,SUSTIVA,Proteinuria,,,,,97675803,1,200906,,,,97675803,1,HIV infection
9808461,98084612,2,F,,20100924,20140110,20150731,PER,,US-GILEAD-2010-0032140,GILEAD,,66,YR,,F,Y,,,20150731,N,MD,US,US,SUSTIVA,Creatinine renal clearance decreased;Fanconi syndrome acquired,98084612,OT,,,,,,,,,98084612,1,HIV infection
9813782,98137822,2,F,,20150807,20140113,20150813,EXP,,FR-GILEAD-2014-0091571,GILEAD,,,,,,Y,,,20150813,N,MD,FR,FR,SUSTIVA,Ventricular hypoplasia,98137822,OT,,,98137822,1,20130930,20130930,,,98137822,1,HIV infection
9813845,98138452,2,F,,20100826,20140113,20150727,PER,,US-GILEAD-2010-0031454,GILEAD,,27,YR,A,,Y,,,20150727,N,MD,US,US,SUSTIVA,Rash,,,,,,,,,,,98138452,1,HIV infection
9828052,98280523,3,F,2010,20100810,20140117,20150722,PER,,US-GILEAD-2010-0030788,GILEAD,,59,YR,A,M,Y,,,20150722,N,CN,US,US,SUSTIVA,Drug ineffective,,,,,98280523,1,2010,2010,,,98280523,1,HIV infection
9828107,98281072,2,F,,20101015,20140117,20150722,PER,,US-GILEAD-2010-0032714,GILEAD,,31,YR,,M,Y,,,20150722,N,OT,US,US,SUSTIVA,Anxiety;Dysarthria;Gait disturbance;Tremor,,,,,98281072,1,20100903,,,,,,
9828111,98281112,2,F,,20101025,20140117,20150722,PER,,US-GILEAD-2010-0033116,GILEAD,,,,,F,Y,,,20150722,N,CN,US,US,SUSTIVA,Blood lactic acid increased;Blood pressure decreased;Dyspnoea,,,,,,,,,,,98281112,1,HIV infection
9828120,98281202,2,F,,20101118,20140117,20150722,PER,,US-GILEAD-2010-0034090,GILEAD,,,,,M,Y,,,20150722,N,MD,US,US,SUSTIVA,Rash,,,,,98281202,1,20101118,,,,98281202,1,Chronic hepatitis B
9828121,98281212,2,F,,20101028,20140117,20150722,PER,,US-GILEAD-2010-0033133,GILEAD,,,,,M,Y,,,20150722,N,MD,US,US,SUSTIVA,Mental impairment,,,,,,,,,,,98281212,1,HIV infection
9828194,98281943,3,F,201009,20110602,20140117,20150722,PER,,US-GILEAD-2010-0032732,GILEAD,,,,A,M,Y,,,20150722,N,OT,US,US,SUSTIVA,Dyspnoea;Tremor,,,,,98281943,1,201009,201009,,,98281943,1,HIV infection
9847155,98471553,3,F,20131105,20140227,20140127,20150722,PER,,US-BMSGILMSD-2014-0093029,GILEAD,,54,YR,A,M,Y,,,20150722,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective,98471553,OT,,,98471553,1,20101017,,,,98471553,1,HIV infection
9871069,98710693,3,F,20130206,20130306,20140205,20150723,PER,,US-GILEAD-2013-0069855,GILEAD,,59,YR,A,M,Y,,,20150723,N,OT,US,US,SUSTIVA,Anger;Anxiety;Depression;Lethargy;Obsessive thoughts;Somnolence,,,,,98710693,1,20130201,,,,98710693,1,HIV infection
9885667,98856673,3,F,1999,20110921,20140210,20150731,PER,,US-GILEAD-2011-0037125,GILEAD,,,,,M,Y,59.87,KG,20150731,N,MD,US,US,EFAVIRENZ,Renal failure,98856673,OT,,,98856673,1,201010,201010,,,98856673,1,HIV infection
9892010,98920103,3,F,,20140226,20140212,20150722,PER,,US-GILEAD-2014-0094090,GILEAD,,48,YR,A,F,Y,61.22,KG,20150722,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intentional product misuse,,,,,,,,,,,98920103,1,Acquired immunodeficiency syndrome
9917734,99177342,2,F,,20140219,20140221,20150722,PER,,US-GILEAD-2014-0095008,GILEAD,,52,YR,A,F,Y,,,20150722,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pruritus,,,,,,,,,,,99177342,1,Product used for unknown indication
9985498,99854982,2,F,,20120918,20140307,20150722,PER,,US-GILEAD-2012-0061629,GILEAD,,47,YR,A,M,Y,,,20150722,N,PH,US,US,SUSTIVA,Mental impairment,,,,,,,,,,,,,
9985506,99855062,2,F,20110721,20120727,20140307,20150727,PER,,MX-GILEAD-2012-0059012,GILEAD,,41,YR,A,M,Y,79.5,KG,20150727,N,MD,MX,US,EFAVIRENZ,Abnormal dreams;Dizziness;Insomnia,,,,,99855062,1,20110721,,,,99855062,1,HIV infection
